



Dual DNA and Protein Tagging of Open Chromatin Unveils Dynamics of Epigenomic Landscapes in Leukemia

Citation

Lee, Jonathan D, Joao A Paulo, Ryan R Posey, Vera Mugoni, Nikki R Kong, Giulia Cheloni, Yu-Ru Lee, et al. 2021. "Dual DNA and Protein Tagging of Open Chromatin Unveils Dynamics of Epigenomic Landscapes in Leukemia." *Nature Methods* 18 (3): 293–302.

Published Version

<https://doi.org/10.1038/s41592-021-01077-8>

Permanent link

<https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37373075>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

1 **Dual DNA and protein tagging of open chromatin unveils dynamics of**
2 **epigenomic landscapes in leukemia**

3

4 Jonathan D. Lee^{1,2,3,4*}, Joao A. Paulo⁵, Ryan R. Posey^{1,2,3}, Vera Mugoni^{1,2,3}, Nikki R. Kong⁶,
5 Giulia Cheloni^{1,2,3}, Yu-Ru Lee^{1,2,3,7}, Frank J. Slack⁸, Daniel G. Tenen^{6,9}, John G. Clohessy^{1,2,3,10},
6 Steven P. Gygi⁵ & Pier Paolo Pandolfi^{1,2,3,11,12*}

7

8 ¹Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School,
9 Boston, Massachusetts, USA.

10 ²Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard
11 Medical School, Boston, Massachusetts, USA.

12 ³Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, USA.

13 ⁴Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge,
14 Massachusetts, USA.

15 ⁵Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.

16 ⁶Harvard Stem Cell Institute, Boston, Massachusetts, USA.

17 ⁷Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

18 ⁸HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical
19 Center, Harvard Medical School, Boston, Massachusetts, USA.

20 ⁹Cancer Science Institute of Singapore, Singapore, Singapore.

21 ¹⁰Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard
22 Medical School, Boston, Massachusetts, USA.

23 ¹¹MBC, Department of Molecular Biotechnology and Health Sciences, University of Torino,
24 Torino, Italy.

25 ¹²Renown Institute for Cancer, Nevada System of Higher Education, Reno, Nevada, USA.

26

27 *Correspondence to: jdlee@post.harvard.edu and pierpaolo.pandolfiderinaldis@renown.org

28

29 **Abstract**

30 The architecture of chromatin specifies eukaryotic cell identity by controlling transcription factor
31 access to sites of gene regulation. Here we describe a dual transposase/peroxidase approach,
32 integrative DNA And Protein Tagging (iDAPT), which detects both DNA (iDAPT-seq) and protein
33 (iDAPT-MS) associated with accessible regions of chromatin. In addition to direct identification
34 of bound transcription factors, iDAPT enables the inference of their gene regulatory networks,
35 protein interactors, and regulation of chromatin accessibility. We applied iDAPT to profile the
36 epigenomic consequences of granulocytic differentiation of acute promyelocytic leukemia,
37 yielding previously undescribed mechanistic insights with potential therapeutic implications. Our
38 findings demonstrate the power of iDAPT as a discovery platform for both the dynamic
39 epigenomic landscapes and their transcription factor components associated with biological
40 phenomena and disease.

41

42

43 **Introduction**

44 In the eukaryotic cell, DNA and protein intertwine as chromatin, forming a dynamic landscape
45 comprised of genes, their regulatory sequence elements, and the transcription factor complexes
46 modulating gene expression¹⁻³. To perform their regulatory activities, transcription factor
47 components require access to these encoded DNA elements, otherwise impeded by
48 nucleosomal occupancy or higher-order steric hindrance^{4,5}. These regions of open chromatin
49 are continuously remodeled to control access of the transcriptional machinery and to modulate
50 gene expression^{4,6}. Thus, profiles of accessible genomic regions and their corresponding
51 proteomes would provide a comprehensive framework to understand genome-wide
52 transcriptional regulation, especially as it applies to cellular identity or disease.

53 While sequence-based profiling methods of open chromatin, such as DNase
54 hypersensitivity^{6,7} and the assay for transposase-accessible chromatin using sequencing
55 (ATAC-seq)⁸, have expanded our understanding of the interplay between chromatin states and
56 transcription, identification of the transcription factor components associated with these
57 accessible chromatin regions remains inferential from these datasets⁹. Specifically, these
58 bioinformatic “footprinting” approaches are limited to sequence-specific transcription factors with
59 long residence times on chromatin, despite known binding of a number of transcription factors
60 with undetectable footprints^{9,10}. On the other hand, mass spectrometry-based methods have
61 emerged to characterize proteins associated with open chromatin directly such as through
62 chromatin fractionation¹¹⁻¹⁴, yet these approaches neither specify differentially bound genomic
63 loci nor provide insight into their transcriptional regulatory activity. To bridge these two
64 approaches, we developed an integrative DNA And Protein Tagging (iDAPT) platform,
65 combining biochemical enrichment via a bifunctional transposase/peroxidase probe and
66 bioinformatic analysis of both genomic and proteomic profiles of open chromatin, attainable from
67 a single nuclear lysate preparation (**Fig. 1a**).

68

69

70 **Results**

71 Tn5 transposase preferentially tags and fragments (tagments) sterically accessible DNA in
72 native chromatin⁸. Because Tn5 transposase remains physically bound to its DNA substrate
73 after insertion of its transposon payload¹⁵, we hypothesized that Tn5 transposase may also
74 serve as an anchor for proximal labeling of proteins associated with open chromatin. The
75 APEX2 peroxidase represents an attractive choice for iDAPT due to its widespread use as a
76 genetic tag for spatially restricted proteomic enrichment, its short labeling timeframe of one
77 minute, and its previously described peroxidase activity as a purified protein^{16,17}. For these
78 reasons, we fused APEX2 with Tn5 transposase for sequential transposition and peroxidase-
79 mediated biotin labeling.

80 We cloned and purified a series of transposase/peroxidase fusion probes consisting of
81 APEX2 peroxidase fused either N- or C-terminal to Tn5 transposase (peroxidase/transposase
82 [PT] and transposase/peroxidase [TP], respectively), adjoined via several linkers (L1-L5)
83 (**Extended Data Fig. 1a-b**). C-terminal peroxidase (TP1-TP5) fusions yielded ATAC-seq library
84 quantifications similar to commercial (Nextera) Tn5 transposase and in-house purified untagged
85 or FLAG-tagged Tn5 transposases (C-terminal FLAG [Tn5-F] and N-terminal FLAG [F-Tn5]),
86 whereas N-terminal peroxidase (PT1-PT5) fusions exhibited decreased transposase activity
87 (**Extended Data Fig. 1c**). DNA fragment size analysis of ATAC-seq libraries generated from all
88 TP fusions yielded distributions corresponding to ~200 base pair-wide nucleosomal periods
89 typically observed with open chromatin enrichment⁸ (**Extended Data Fig. 1d**). Furthermore, we
90 observed an expected gel shift of linearized DNA in the presence of transposase domain-
91 containing enzymes but not in the presence of FLAG-tagged APEX2 domain alone (APEX2-F)¹⁵,
92 with corresponding DNA fragmentation profiles dependent on both transposase-DNA
93 association and absence of the divalent cation chelator EDTA¹⁸ (**Extended Data Fig. 1e-f**).

94 Next, we generated ATAC-seq/iDAPT-seq libraries of GM12878 cells using the recently
95 developed OmniATAC protocol, which improves signal-to-noise ratios, decreases mitochondrial
96 read proportions, and increases assay reproducibility as compared to the original ATAC-seq
97 protocol, with Nextera Tn5, in-house purified Tn5-F, and representative fusion probes TP3 and
98 TP5¹⁹. Here we distinguish iDAPT-seq from ATAC-seq with the use of TP fusion enzymes for
99 tagmentation, allowing for subsequent proteomic labeling and enrichment (**Fig. 1a**). ATAC-seq
100 and iDAPT-seq libraries exhibited similar nucleosomal periodicities in their fragment size
101 distributions, high signal-to-noise ratios, and broad decreases in mitochondrial read proportions
102 relative to published GM12878 ATAC-seq libraries generated via the original ATAC-seq
103 protocol^{8,18-20} (**Extended Data Fig. 2a-c**). Furthermore, TP3 and TP5 iDAPT-seq libraries

104 exhibit high correlations with Tn5 transposase-generated ATAC-seq libraries (**Fig. 1b-c,**
105 **Extended Data Fig. 2d**). Thus, TP3 and TP5 fusion enzymes yield high quality iDAPT-seq
106 libraries, akin to ATAC-seq libraries generated via Tn5 transposase enzyme lacking a
107 peroxidase domain.

108 As further assessment of TP localization to open chromatin, we performed ATAC-seq, an
109 assay of *in situ* transposase activity and localization¹⁸, with co-immunofluorescence of various
110 markers of chromatin state. TP3 and Tn5-F exhibit similarly positive correlations with histone H3
111 lysine 27 acetylation (H3K27Ac) and RNA polymerase II serine-2 phosphorylation (RNAPII S2P)
112 immunofluorescence signals, markers of transcriptionally active chromatin, and similarly poor
113 correlations with H3 lysine 9 trimethylation (H3K9me3) immunofluorescence, a marker of
114 transcriptionally inactive chromatin, albeit with slight differences in colocalization patterns
115 between the two probes (**Fig. 1d-e**). These data indicate that our TP fusion probes retain native
116 Tn5 transposase activity and preferentially tag open chromatin.

117 Having confirmed TP fusion tagging of and localization to open chromatin, we next
118 assessed APEX2 peroxidase functionality when fused with Tn5 transposase. First to confirm
119 this, we added 1 mM hydrogen peroxide to purified proteins alone and detected peroxidase
120 activity from the fusion proteins via resorufin fluorescence after one minute (**Supplementary**
121 **Fig. 1a-b**). Interestingly, all TP fusions exhibit higher peroxidase activities than APEX2-F alone,
122 possibly due to increased thermal stability or heme binding of APEX2 dimer formation induced
123 by the proximity of the two C-termini of dimeric Tn5 transposase^{16,21-23} (**Supplementary Fig.**
124 **1c**). Next, in extracted HEK293T nuclei, we observed strong peroxidase-dependent biotin signal
125 in the presence of the TP3 fusion probe and low signal in the presence of the negative control
126 probes Tn5-F and APEX2-F (**Supplementary Fig. 2**). Residual APEX2-F-mediated signal
127 further decreased with additional washing and blocking steps while maintaining strong TP3-
128 mediated biotin signal (**Supplementary Fig. 2**). In line with our hypothesis that Tn5 transposase
129 remains physically bound to native chromatin, Tn5 transposase and TP3 fusion enzyme are
130 found in the nuclear lysate, whereas APEX2 is mostly lost despite equimolar addition of
131 recombinant protein to the tagmentation buffer (**Supplementary Fig. 1a, 2b-c**). Indeed, we
132 found all TP fusion enzymes to promote strong biotin labeling in K562 nuclei, with TP5 and TP3
133 enzymes exhibiting the highest levels of labeling (**Extended Data Fig. 3a**). Finally, we
134 confirmed that this labeling is dependent on the presence of both hydrogen peroxide and biotin-
135 phenol (**Extended Data Fig. 3b**). Thus, our findings indicate that TP probes label transposase-
136 accessible chromatin in a peroxidase-dependent manner.

137 With our optimized iDAPT protocol, we performed quantitative mass spectrometry on the
138 iDAPT-enriched proteome (iDAPT-MS) from K562 nuclei²⁴ (**Fig. 2a, Supplementary Table 1**).
139 As negative control probes enrich for nonspecific background signal, akin to an IgG negative
140 control for an immunoprecipitation assay, we interpreted the substantial proteomic content
141 enriched by TP over negative control probes as *bona fide* proteins proximal to Tn5 transposase
142 localization in isolated nuclei (**Fig. 2b**). By hierarchical clustering and correlation analyses,
143 nuclear lysates labeled via TP3 and TP5 segregate from lysates labeled via single enzymatic
144 domains, with substantial overlap between TP3- and TP5-enriched proteomes (**Extended Data**
145 **Fig. 3c-d**). We observed a similarly substantial iDAPT-MS enrichment pattern from TP3 versus
146 negative control probes from the NB4 cell line, incorporating an additional wash step to block
147 endogenous peroxidase activity prior to tagmentation and biotin labeling (**Extended Data Fig. 4,**
148 **Supplementary Table 2**).

149 To validate highly enriched proteins by iDAPT-MS, we performed CUT&RUN (ERH and
150 WBP11) and analyzed published ENCODE ChIP-seq datasets from the K562 cell line^{25,26}
151 (**Supplementary Table 3**). We found substantial enrichment of protein binding at sites of open
152 chromatin (**Fig. 2c, Extended Data Fig. 5**). These results demonstrate the ability of iDAPT-MS
153 to discover proteins associated with open chromatin.

154 Next, we performed enrichment analyses of our iDAPT-MS datasets. Subcellular enrichment
155 analysis identified nuclear speckles and nucleoplasm in both K562 and NB4 iDAPT-MS
156 datasets²⁷ (**Extended Data Fig. 6a-b**). Indeed, ATAC-seq signal of Tn5-F colocalizes with the
157 nuclear speckle marker SC35 in multiple cell lines, in agreement with recent reports of nuclear
158 speckle localization at active promoters^{28,29} (**Fig. 2d, Extended Data Fig. 6c-e**). We further
159 identified significant enrichment of protein complexes such as Mediator, which regulates
160 communication from enhancer- and promoter-bound transcription factors to RNA polymerase
161 II³⁰, and BAF, which remodels chromatin accessibility³¹, in both K562 and NB4 cell lines³² (**Fig.**
162 **2e-f**). Chromatin remodelers and RNA-binding proteins were highly represented (>50% of
163 annotated proteins) among enriched proteins, whereas transcription factors and histone variants
164 were not as well represented (<25% of annotated proteins) (**Extended Data Fig. 6f**). While
165 histone protein H2AX/H2AFX was highly enriched in both NB4 and K562 iDAPT-MS proteomes,
166 other detected histone proteins were weakly enriched over negative control probes or not
167 detected, suggesting that histone proteins as a class are not predominantly enriched by iDAPT-
168 MS (**Fig. 2b, Extended Data Fig. 4c, 6f-g**).

169 Despite low background peroxidase signal, APEX2-F yields some proteomic enrichment
170 over Tn5-F, although not as strongly as signal generated by TP3/TP5 (**Supplementary Fig. 3a-**

171 f). To assess whether APEX2-F has a different labeling propensity over TP3/TP5 fusion probes
172 in K562 nuclei, we used quantile normalization as a proxy for normalizing APEX2-F peroxidase
173 activity with TP3 and TP5 activities (**Supplementary Fig. 3g**). We found this quantile
174 normalization scheme to yield similar subcellular enrichment patterns, albeit with increased
175 mitochondrial enrichment, as with our primary streptavidin/trypsin peptide normalization scheme
176 (**Extended Data Fig. 6a, Supplementary Fig. 3h**). Taken together, these data suggest that TP
177 fusion proteins exhibit different labeling patterns from diffusely nuclear APEX2.

178 Next, we compared iDAPT-MS enrichment relative to other techniques used to assess
179 protein abundance on chromatin. First, we collated sets of detected proteins from K562 RNA-
180 seq (protein-coding transcripts)²⁵, whole cell proteome³³, and nuclear proteome³⁴ datasets and
181 then assessed the proportions of proteins detected across subcellular compartments in each of
182 these datasets to normalize for proteome complexity. While we observed mild subcellular
183 enrichment differences between RNA-seq and whole cell proteome datasets, we found
184 increased enrichment of nucleoli, nucleoplasm, and nucleus localization terms from iDAPT-MS
185 and nuclear proteome datasets (**Supplementary Fig. 4a-b**). The K562 iDAPT-MS-enriched
186 proteome exhibits increased enrichment of nuclear speckles, nucleoplasm, and nuclear body
187 localization terms and decreased cytosolic, plasma membrane, and Golgi apparatus localization
188 terms over the nuclear proteome (**Supplementary Fig. 4b**). Second, we assessed how iDAPT-
189 MS enrichment compares with incremental salt extractions from K562 nuclei, partitioning
190 euchromatic and heterochromatic proteins via disrupting electrostatic protein-protein and
191 protein-DNA interactions³⁴ (**Supplementary Fig. 4c-d**). After converting protein sets to
192 subcellular enrichment scores and performing principal component analysis, we found that K562
193 iDAPT-MS coincides with proteins identified by both isotonic and 250 mM salt extractions along
194 the first principal component, largely representing euchromatic proteins. Third, we compared
195 iDAPT-MS enrichment with additional published salt extraction- and micrococcal nuclease
196 (MNase) fragmentation-based chromatin proteomic datasets in a similar manner¹²⁻¹⁴
197 (**Supplementary Fig. 4e-f**). Indeed, iDAPT-MS enrichment corresponds with chromatin
198 proteomes enriched by light MNase digestion and salt extraction along the first principal
199 component. Together, these findings demonstrate that iDAPT-MS enriches for the open
200 chromatin proteome.

201 A critical advantage of iDAPT-MS over ATAC-seq/iDAPT-seq or chromatin
202 immunoprecipitation (ChIP)-based approaches is its ability to capture numerous transcription
203 co-factors associated with open chromatin in a single assay, which regulate their associated
204 sequence-specific transcription factors. As proof of principle, we found the MAX protein

205 interaction network to be significantly enriched on open chromatin by K562 iDAPT-MS³⁵ (**Fig.**
206 **2g**). To validate this finding, by ChIP-seq analysis, protein interactors of MAX colocalize more
207 tightly with MAX across the open chromatin landscape than do non-interacting proteins (**Fig. 2h,**
208 **Supplementary Table 3**). Therefore, iDAPT-MS together with protein interaction annotations
209 facilitates the identification of active transcription factor protein complexes on open chromatin,
210 expanding the inference of *cis*-regulatory transcription factor networks.

211 Transcription factors regulate gene expression by binding to DNA in a sequence-specific
212 manner and recruiting transcriptional activators and/or repressors to their target genes. Most
213 transcription factors are found within regions of open chromatin, a pattern we also observed in
214 our iDAPT-MS data^{3,6,36} (**Fig. 3a, Extended Data Fig. 7a**). As iDAPT enables profiling of both
215 genomic and proteomic content of the open chromatin landscape, we sought to compare
216 transcription factor enrichment profiles obtained from iDAPT-MS and iDAPT-seq approaches.
217 To assess the enrichment of transcription factors obtained via iDAPT-seq, we profiled both
218 nuclei and “naked” genomic DNA from both K562 and NB4 cell lines. iDAPT-seq analysis
219 confirms loss of both nucleosomal enrichment and promoter insertion preference in naked DNA;
220 furthermore, insertion profiles segregate along the first principal component and exhibit skewed
221 statistical significance towards chromatinized peaks in both datasets (**Extended Data Fig. 7b-h**).

222 With these iDAPT-seq profiles, we performed footprinting analysis to infer transcription
223 factor activities at their cognate motifs. By a genome-wide bivariate footprinting approach,
224 accounting for both transcription factor footprint depth (FPD) and flanking chromatin
225 accessibility (FA) near the transcription factor motif, we observed significant enrichment of most
226 CisBP transcription factor motifs in iDAPT-seq profiles from native chromatin^{10,36} (**Fig. 3b-c,**
227 **Extended Data Fig. 8a-c**). We categorized motifs emerging from our footprint analysis into
228 three classes: strong footprinting (class A), weak footprinting (class B), and no or negative
229 footprinting (class C) (**Extended Data Fig. 8d**). In line with previous reports, transcription
230 factors with longer residence times on chromatin exhibit stronger footprints: for instance, CTCF,
231 an insulator protein with a long retention time on DNA, exhibits a strong footprint (class A) and is
232 detected by both iDAPT-MS and ChIP-seq^{9,37} (**Fig. 3d**). RELA/NF- κ B complexes (class B) have
233 short DNA residence times and substantially weaker footprinting potential, despite being
234 detected by both iDAPT-MS and ChIP-seq³⁸ (**Fig. 3e**). While class C motifs such as IKZF1
235 exhibit nonsignificant or even significantly negative footprinting activity, several of these
236 transcription factors are nonetheless found on open chromatin by both iDAPT-MS and ChIP-seq
237 (**Fig. 3f-h**). Broadly, we observed no clear relationship between inferred transcription factor
238 footprint activity by iDAPT-seq and magnitude of transcription factor abundance by iDAPT-MS

239 (Fig. 3g, Extended Data Fig. 8e). Indeed, ChIP-seq and iDAPT-MS both directly identify
240 transcription factors spanning all three classes of footprint activities (Fig. 3h, Supplementary
241 Table 3), yet neither assay alone can inform how transcription factor binding might affect
242 chromatin accessibility. Conversely, footprinting analysis of iDAPT-seq is able to detect changes
243 to chromatin accessibility, but these changes may be independent of whether a transcription
244 factor is bound or not. Thus, we posit that, for the analysis of transcription factors with annotated
245 motifs, iDAPT-seq and iDAPT-MS together identify transcription factors bound to open
246 chromatin and reveal their activity on chromatin accessibility as a consequence of their
247 abundance, providing greater insight into transcription factor mechanisms than either assay
248 alone.

249 Next, we assessed how transcription factor abundances and chromatin accessibility states
250 correlate upon granulocytic differentiation of the NB4 acute promyelocytic leukemia (APL) cell
251 line. Differentiation of NB4 cells via all-*trans* retinoic acid (ATRA) leads to degradation of the
252 PML-RARA oncogenic fusion protein, decreased proliferation, and granulocytic differentiation of
253 the leukemia³⁹ (Fig. 4a-b, Extended Data Fig. 9a-c). iDAPT-MS reveals a dramatic shift in the
254 open chromatin proteome, with profiles clustering by treatment (Extended Data Fig. 4b, d). In
255 line with previous reports, we observed negative enrichment of RARA, degraded upon ATRA
256 treatment^{40,41}, and positive enrichment of PU.1/SPI1, CEBPB, and CEBPE, upregulated in
257 response to ATRA⁴²⁻⁴⁴ (Extended Data Fig. 9d). Pathway enrichment analysis reveals positive
258 associations with MAPK signaling, neutrophil differentiation, and the innate immune response
259 (Extended Data Fig. 9e). On the other hand, loss of histone deacetylase enrichment, the most
260 significantly negative pathway, may explain the previously described decrease in histone
261 acetylation states and sensitivity to histone deacetylase inhibitors in APL^{45,46}. These
262 observations validate the ability of iDAPT-MS to capture both specific proteins and proteomic
263 signatures as they dynamically shift upon changes in cell identity.

264 Given the different transcription factor classes captured by iDAPT at steady state, we
265 explored how transcription factor activities and abundances change on open chromatin upon
266 ATRA-mediated cellular differentiation. By iDAPT-seq, we observed both increased and
267 decreased regions of open chromatin and motif footprinting activity upon ATRA treatment, with
268 footprinting parameters FPD and FA correlating strongly with composite footprinting scores
269 (Supplementary Fig. 5). Intriguingly, both concordant and discordant enrichment patterns
270 between iDAPT-seq and iDAPT-MS transcription factor enrichment profiles were observed (Fig.
271 4c). Furthermore, some transcription factors exhibit only one of either differential footprinting or
272 protein abundance, discrepancies that have been observed previously between chromatin

273 accessibility and chromatin immunoprecipitation-based assays^{9,10} (**Fig. 4c**). To corroborate our
274 findings, we replaced our iDAPT-seq footprinting and iDAPT-MS analyses with either motif
275 enrichment analysis via ChromVAR or RNA-seq analysis, which correlates well with our iDAPT-
276 MS protein analysis, both yielding similar transcription factor patterns⁴⁷⁻⁴⁹ (**Supplementary Fig.**
277 **6-7**). Hence, iDAPT reveals nine distinct classes (classes I-IX) arising as a consequence of
278 integrating both iDAPT-seq, a readout of transcription factor activity, and iDAPT-MS, a readout
279 of transcription factor protein abundance at open chromatin (**Fig. 4c, Extended Data Fig. 10a**).
280 Furthermore, we interpreted concordance (classes III, VII) as chromatin activating activity by the
281 transcription factor of interest and discordance (classes I, IX) as chromatin repression (**Fig. 4c,**
282 **Extended Data Fig. 10a**). In support of this functional classification scheme, among
283 transcription factors decreasing in abundance upon ATRA treatment, those classified as
284 activating (class VII), which should be easier to tag by TP fusion proteins in the vehicle-treated
285 setting, are generally more enriched by TP3 over negative control probes than repressive
286 transcription factors (class I) (**Extended Data Fig. 10b**). Thus, iDAPT-MS and iDAPT-seq
287 together uncover functional relationships between transcription factor binding dynamics and
288 chromatin accessibility, which neither assay can elucidate alone.

289 As iDAPT-MS reveals abundance changes of proteins beyond transcription factors, we
290 assessed how proteins interacting with transcription factors may cooperate to regulate
291 chromatin accessibility states. For a given transcription factor, we superimposed iDAPT-MS
292 protein abundance changes onto its first-order protein interaction network from BioGrid³⁵. Of
293 these putative transcription factor complex profiles, we found the PU.1/SPI1 protein interaction
294 network to be the most significantly decreased complex upon ATRA treatment (**Fig. 4d**).
295 Intriguingly, while many of its protein interactors such as the transcriptional corepressor SIN3A
296 decrease in abundance, PU.1/SPI1 itself increases in abundance to promote chromatin
297 accessibility at its cognate motif (class III)^{42,50} (**Fig. 4d-e**). Furthermore, the decrease in RARA
298 protein abundance, also an interactor of PU.1/SPI1, leads to increased chromatin accessibility
299 at its binding motif due to its ATRA-mediated degradation, implicating its transcriptional
300 repressive activity (class I)⁵¹ (**Supplementary Fig. 8a**). Thus, in the APL setting, transcriptional
301 repressors bind to PU.1/SPI1 to repress chromatin accessibility at PU.1/SPI1 motifs; this
302 repressive binding is relieved upon ATRA treatment, enabling PU.1/SPI1 to activate
303 transcription at its motifs. This analysis may be extended to other transcription factors and their
304 protein complexes: BCL11A, together with many of its annotated protein interactors, decreases
305 in abundance while increasing chromatin accessibility upon ATRA treatment (class I),
306 suggestive of a coordinated downregulation of this repressive transcription factor and its protein

307 complex components⁵² (**Fig. 4f-g**). While JUNB⁵³⁻⁵⁵, CEBPB⁵⁶, and CEBPE⁵⁷ have both
308 activating and repressive behaviors reported, we observed class VII activating behavior from the
309 JUNB transcription factor and class IX repressive behavior from the CEBPB and CEBPE
310 transcription factors upon ATRA treatment, with their dynamic protein complex components
311 providing potential context-specific insights into their regulatory activities on chromatin state
312 (**Supplementary Fig. 8b-c**). In this manner, integrating protein interaction information with
313 iDAPT-MS and iDAPT-seq profiles reveals the interplay between transcription factors, their
314 activities on chromatin accessibility, and their putative protein complexes as these components
315 change during ATRA treatment of NB4 cells.

316 Given the numerous transcription factors and associated components differentially bound at
317 open chromatin upon ATRA treatment, some of these newly identified proteins may have
318 functional roles in APL differentiation. We superimposed our iDAPT-MS results with NB4
319 genetic dependencies and identified both PML and RARA, corroborating our analysis⁵⁸ (**Fig. 4h**).
320 After filtering out essential genes across hematopoietic cell lines, we identified a number of
321 candidate transcription factor effectors, including CEBPA, EBF3, and ZEB2, which may act
322 downstream or independently of PML-RARA (**Fig. 4h, Supplementary Fig. 9**). In agreement
323 with previous reports, our transcription factor classification scheme assigns ZEB2 as
324 repressive⁵⁹ (class I) and EBF3⁶⁰⁻⁶² and CEBPA⁶³ as activating (class VII) (**Fig. 4c,**
325 **Supplementary Fig. 9c-d**). This analysis reifies the power of combining forward genetic
326 screens with iDAPT-MS to identify critical transcription factors and their regulators for a given
327 biological phenotype.

328 Finally, we assessed how our interpretations of transcription factor dynamics would change
329 between iDAPT-MS, measuring protein abundances directly, and RNA-seq profiles. While we
330 observed a positive correlation between iDAPT-MS and RNA-seq profiles upon ATRA treatment,
331 several discordant cases emerged, including JUNB/JUND and RARA, with their RNA-seq effect
332 sizes opposite in magnitude of their corresponding iDAPT-MS effects (**Fig. 4c, Supplementary**
333 **Fig. 7b-c**). Indeed, ATRA binds to RARA, and prolonged ligand binding and transcriptional
334 activity leads to RARA protein degradation⁴⁰ (**Supplementary Fig. 8a**). Furthermore, as
335 transcript levels of RARA and several other protein interactors of PU.1/SPI1 do not fully match
336 iDAPT-MS enrichment trends, the significantly negative enrichment of the PU.1/SPI1 protein
337 complex observed upon ATRA treatment by iDAPT-MS is lost by RNA-seq (**Supplementary Fig.**
338 **10**). Thus, among open chromatin-associated proteins, bulk RNA-seq may broadly provide
339 similar patterns as iDAPT-MS, but discrepancies between the two limit the ability of RNA-seq to
340 replace proteomic analysis.

341

342

343 **Discussion**

344 In summary, we have developed iDAPT to capture both the genomic and proteomic contents of
345 open chromatin, realized via a recombinant transposase/oxidase probe. Integrative analysis
346 of iDAPT-seq and iDAPT-MS profiles reveals nine transcription factor classes based on both
347 changes in protein abundance on open chromatin (decreased, unchanged, or increased) and
348 transcription factor activity (closed, unchanged, open) (**Fig. 4c, Extended Data Fig. 10a**).
349 Furthermore, iDAPT-MS together with protein interaction annotations implicates changes in
350 transcription factor complex compositions that may explain the corresponding changes in
351 chromatin accessibility (**Fig. 4d-g, Supplementary Figs. 8-9**). Identification of such
352 relationships between transcription factors, their protein complex components, and their
353 functional outputs on chromatin accessibility may be informative for mechanistic and therapeutic
354 study, especially in conjunction with genetic screening approaches. Indeed, in the context of
355 APL, our analyses suggest targets for which approved therapies already exist, such as histone
356 deacetylases, and those which may warrant further investigation, such as EBF3 and ZEB2.

357 From our transcription factor classification scheme, we are able to assign activating or
358 repressive activities to sequence-specific transcription factors based on their concordance or
359 discordance between iDAPT-MS and iDAPT-seq profiles. At the heart of this finding is the
360 question, if repressive factors close chromatin at their cognate binding sites, how are they still
361 detected by iDAPT-MS? Due to chromatin “breathing” or stochastic transposition, Tn5
362 transposase may insert proximal to repressive transcription factors on chromatin, albeit at a
363 decreased frequency as compared to activating transcription factors, enabling the tagging of
364 such repressive factors for mass spectrometry detection. In support of this explanation, as in
365 **Fig. 4g and Supplementary Figs. 8a and c**, repressive transcription factors (classes I and IX)
366 exhibit detectable transposase activity proximal to their cognate binding motifs above
367 background in both ATRA- and control-treated cells. On the other hand, the inference of
368 transcription factor activity via genome-wide footprinting from iDAPT-seq/ATAC-seq datasets
369 may be partially artifactual, leading to misleading classifications of transcription factor activity.
370 First, footprinting analysis relies on the quality of curated DNA binding motifs, whereas actual
371 transcription factor localization to open chromatin may not be restricted to such motif-containing
372 chromatin regions. Second, genome-wide footprinting analysis in bulk may mask locus-specific
373 or cell-specific transcription factor activities, a consequence of broadly enriching for
374 transposase-accessible chromatin, only one of many regulatory features of gene expression.
375 Thus, the combination of iDAPT-MS and iDAPT-seq provides a powerful opportunity to identify

376 such key relationships between transcription factor abundance and genome-wide regulation of
377 chromatin accessibility.

378 In addition to chromatin accessibility state, additional factors such as histone and DNA
379 modifications may modulate transcription factor activity at a given genetic locus²⁵. To explore
380 these relationships further, complementary methods to identify the transcription factors and
381 associated proteins at these specific chromatin states include ChIP-based enrichment⁶⁴ and
382 proximity labeling via chromatin reader domains⁶⁵. At a finer genetic resolution are locus-
383 specific enrichment methods, including recently developed CRISPR/Cas9-based proximity
384 labeling approaches^{11,66}. Integrating these methods with assays of the accessible genome such
385 as ATAC-seq may reveal context-specific transcription factor activities and protein complex
386 compositions that iDAPT would not reveal. On the other hand, classification of global
387 transcription factor activities via iDAPT may better inform their regulation of cellular phenotypes,
388 encompassing mechanistic information across all of its binding sites. Furthermore, as iDAPT
389 does not require genetic manipulation of biological samples of interest as with traditional APEX2
390 or biotin ligase genetic tagging^{16,17,66}, our approach may be readily applied to numerous
391 biological systems to uncover novel chromatin-level molecular correlates and mechanistic
392 insights. Thus, our findings substantiate the unprecedented capability of iDAPT to unravel
393 epigenomic landscapes as they change during development and disease.

394

395 **Acknowledgments**

396 We thank J. Boehm, P. Cheung, J. Harper, J. Heo, P. Kharchenko, and all members of the
397 Pandolfi laboratory for their input. We are grateful to the Harvard Medical School Biopolymers
398 Facility, Harvard Medical School Research Computing, and BIDMC Confocal Imaging Core for
399 their assistance and support. This work was supported in part by the Ludwig Center at Harvard,
400 the Singapore Ministry of Health's National Medical Research Council under its Singapore
401 Translational Research (STaR) Investigator Award, the National Research Foundation
402 Singapore and the Singapore Ministry of Education under its Research Centres of Excellence
403 initiative, a Harvard Medical School Innovation Grant Program grant awarded to J.D.L., and
404 National Institutes of Health (NIH) grants R01 GM132129 to J.A.P., R35 CA232105 to F.J.S.,
405 R35 CA197697 and P01 HL131477 to D.G.T., GM67945 to S.P.G., and R35 CA197529 to
406 P.P.P.

407

408 **Author Contributions**

409 J.D.L. conceived the project, supervised the study, designed and performed experiments,
410 carried out computational analyses, and wrote the manuscript. J.A.P. performed mass
411 spectrometry analyses. R.R.P. designed and performed experiments and performed image
412 analyses. V.M. designed and performed experiments. N.R.K. designed and performed
413 experiments. G.C. designed and performed experiments. Y.-R.L. designed and performed
414 experiments. F.J.S. supervised the study. D.G.T. supervised the study. J.G.C. supervised the
415 study. S.P.G. supervised the study. P.P.P. conceived the project, supervised the study, and
416 wrote the manuscript.

417

418 **Ethics Declaration**

419 J.D.L., J.G.C., and P.P.P. have filed a patent describing iDAPT. All other authors declare no
420 competing interests.

421

422 **References**

- 423 1. Kornberg, R. and Lorch, Y. Chromatin Structure and Transcription. *Annu. Rev. Cell Dev.*
424 *Biol.* **8**, 563–587 (1992).
- 425 2. Gerstein, M. B. *et al.* Architecture of the human regulatory network derived from
426 ENCODE data. *Nature* **489**, 91–100 (2012).
- 427 3. Lambert, S. A. *et al.* The Human Transcription Factors. *Cell* **172**, 650–665 (2018).
- 428 4. Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory
429 epigenome. *Nat. Rev. Genet.* **20**, 207–220 (2019).
- 430 5. Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. *Nat. Rev.*
431 *Genet.* **17**, 487–500 (2016).
- 432 6. Thurman, R. E. *et al.* The accessible chromatin landscape of the human genome. *Nature*
433 **489**, 75–82 (2012).
- 434 7. Boyle, A. P. *et al.* High-Resolution Mapping and Characterization of Open Chromatin
435 across the Genome. *Cell* **132**, 311–322 (2008).
- 436 8. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J.
437 Transposition of native chromatin for fast and sensitive epigenomic profiling of open
438 chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* **10**, 1213–8
439 (2013).
- 440 9. Sung, M.-H., Baek, S. & Hager, G. L. Genome-wide footprinting: ready for prime time?
441 *Nat. Methods* **13**, 222–228 (2016).
- 442 10. Baek, S., Goldstein, I. & Hager, G. L. Bivariate Genomic Footprinting Detects Changes in
443 Transcription Factor Activity. *Cell Rep.* **19**, 1710–1722 (2017).
- 444 11. Wierer, M. & Mann, M. Proteomics to study DNA-bound and chromatin-associated gene
445 regulatory complexes. *Hum. Mol. Genet.* **25**, R106–R114 (2016).
- 446 12. Torrente, M. P. *et al.* Proteomic Interrogation of Human Chromatin. *PLoS One* **6**, e24747
447 (2011).
- 448 13. Alajem, A. *et al.* Differential association of chromatin proteins identifies
449 BAF60a/SMARCD1 as a regulator of embryonic stem cell differentiation. *Cell Rep.* **10**,
450 2019–2031 (2015).
- 451 14. Kulej, K. *et al.* Time-resolved Global and Chromatin Proteomics during Herpes Simplex
452 Virus Type 1 (HSV-1) Infection. *Mol. Cell. Proteomics* **16**, S92–S107 (2017).
- 453 15. Reznikoff, W. S. Transposon Tn5. *Annu. Rev. Genet.* **42**, 269–286 (2008).
- 454 16. Lam, S. S. *et al.* Directed evolution of APEX2 for electron microscopy and proximity
455 labeling. *Nat. Methods* **12**, 51–54 (2014).

- 456 17. Paek, J. *et al.* Multidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed
457 Proximity Labeling. *Cell* **169**, 338-349.e11 (2017).
- 458 18. Chen, X. *et al.* ATAC-seq reveals the accessible genome by transposase-mediated
459 imaging and sequencing. *Nat. Methods* **13**, 1013–1020 (2016).
- 460 19. Corces, M. R. *et al.* An improved ATAC-seq protocol reduces background and enables
461 interrogation of frozen tissues. *Nat. Methods* **14**, 959–962 (2017).
- 462 20. Johnston, A. D., Simões-Pires, C. A., Thompson, T. V., Suzuki, M. & Grealley, J. M.
463 Functional genetic variants can mediate their regulatory effects through alteration of
464 transcription factor binding. *Nat. Commun.* **10**, 3472 (2019).
- 465 21. Martell, J. D., Deerinck, T. J., Lam, S. S., Ellisman, M. H. & Ting, A. Y. Electron
466 microscopy using the genetically encoded APEX2 tag in cultured mammalian cells. *Nat.*
467 *Protoc.* **12**, 1792–1816 (2017).
- 468 22. Mandelman, D., Li, H., Poulos, T. L. & Schwarz, F. P. The role of quaternary interactions
469 on the stability and activity of ascorbate peroxidase. *Protein Sci.* **7**, 2089–2098 (1998).
- 470 23. Davies, D. R., Goryshin, I. Y., Reznikoff, W. S. & Rayment, I. Three-Dimensional
471 Structure of the Tn5 Synaptic Complex Transposition Intermediate. *Science (80-.).* **289**,
472 77–85 (2000).
- 473 24. Navarrete-Perea, J., Yu, Q., Gygi, S. P. & Paulo, J. A. Streamlined Tandem Mass Tag
474 (SL-TMT) Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling
475 Using Tandem Mass Tag-Synchronous Precursor Selection-MS3. *J. Proteome Res.* **17**,
476 2226–2236 (2018).
- 477 25. Encode Consortium. An integrated encyclopedia of DNA elements in the human genome.
478 *Nature* **489**, 57–74 (2012).
- 479 26. Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution
480 mapping of DNA binding sites. *Elife* **6**, (2017).
- 481 27. Thul, P. J. *et al.* A subcellular map of the human proteome. *Science (80-.).* **356**,
482 eaal3321 (2017).
- 483 28. Xiao, R. *et al.* Pervasive Chromatin-RNA Binding Protein Interactions Enable RNA-Based
484 Regulation of Transcription. *Cell* **178**, 107-121.e18 (2019).
- 485 29. Guo, Y. E. *et al.* Pol II phosphorylation regulates a switch between transcriptional and
486 splicing condensates. *Nature* **572**, 543–548 (2019).
- 487 30. Allen, B. L. & Taatjes, D. J. The Mediator complex: A central integrator of transcription.
488 *Nat. Rev. Mol. Cell Biol.* **16**, 155–166 (2015).
- 489 31. Kadoch, C. & Crabtree, G. R. Mammalian SWI/SNF chromatin remodeling complexes

- 490 and cancer: Mechanistic insights gained from human genomics. *Sci. Adv.* **1**, 1–18 (2015).
- 491 32. Ruepp, A. *et al.* CORUM: the comprehensive resource of mammalian protein complexes.
492 *Nucleic Acids Res.* **36**, D646-50 (2008).
- 493 33. Nusinow, D. P. *et al.* Quantitative Proteomics of the Cancer Cell Line Encyclopedia. *Cell*
494 **180**, 387-402.e16 (2020).
- 495 34. Federation, A. J. *et al.* Highly Parallel Quantification and Compartment Localization of
496 Transcription Factors and Nuclear Proteins. *Cell Rep.* **30**, 2463-2471.e5 (2020).
- 497 35. Oughtred, R. *et al.* The BioGRID interaction database: 2019 update. *Nucleic Acids Res.*
498 **47**, D529–D541 (2019).
- 499 36. Weirauch, M. T. *et al.* Determination and inference of eukaryotic transcription factor
500 sequence specificity. *Cell* **158**, 1431–1443 (2014).
- 501 37. Nakahashi, H. *et al.* A genome-wide map of CTCF multivalency redefines the CTCF code.
502 *Cell Rep.* **3**, 1678–1689 (2013).
- 503 38. Bosisio, D. *et al.* A hyper-dynamic equilibrium between promoter-bound and
504 nucleoplasmic dimers controls NF-kappaB-dependent gene activity. *EMBO J.* **25**, 798–
505 810 (2006).
- 506 39. Lanotte, M. *et al.* NB4, a maturation inducible cell line with t(15;17) marker isolated from a
507 human acute promyelocytic leukemia (M3). *Blood* **77**, 1080–6 (1991).
- 508 40. Zhu, J. *et al.* Retinoic acid induces proteasome-dependent degradation of retinoic acid
509 receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. *Proc. Natl. Acad.*
510 *Sci. U. S. A.* **96**, 14807–12 (1999).
- 511 41. de Thé, H. *et al.* The PML-RAR alpha fusion mRNA generated by the t(15;17)
512 translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell*
513 **66**, 675–84 (1991).
- 514 42. Mueller, B. U. *et al.* ATRA resolves the differentiation block in t(15;17) acute myeloid
515 leukemia by restoring PU.1 expression. *Blood* **107**, 3330–8 (2006).
- 516 43. Chih, D. Y., Chumakov, A. M., Park, D. J., Silla, A. G. & Koeffler, H. P. Modulation of
517 mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein
518 gene (C/EBP epsilon). *Blood* **90**, 2987–94 (1997).
- 519 44. Duprez, E., Wagner, K., Koch, H. & Tenen, D. G. C/EBPbeta: a major PML-RARA-
520 responsive gene in retinoic acid-induced differentiation of APL cells. *EMBO J.* **22**, 5806–
521 16 (2003).
- 522 45. Martens, J. H. A. *et al.* PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute
523 Promyelocytic Leukemia. *Cancer Cell* **17**, 173–85 (2010).

- 524 46. Warrell, R. P., He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of
525 transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
526 *J. Natl. Cancer Inst.* **90**, 1621–5 (1998).
- 527 47. Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. chromVAR: inferring
528 transcription-factor-associated accessibility from single-cell epigenomic data. *Nat.*
529 *Methods* **14**, 975–978 (2017).
- 530 48. Witzel, M. *et al.* Chromatin-remodeling factor SMARCD2 regulates transcriptional
531 networks controlling differentiation of neutrophil granulocytes. *Nat. Genet.* **49**, 742–752
532 (2017).
- 533 49. Orfali, N. *et al.* All-trans retinoic acid (ATRA)-induced TFEB expression is required for
534 myeloid differentiation in acute promyelocytic leukemia (APL). *Eur. J. Haematol.* **104**,
535 236–250 (2020).
- 536 50. Hu, Z. *et al.* RUNX1 regulates corepressor interactions of PU.1. *Blood* **117**, 6498–508
537 (2011).
- 538 51. Wang, K. *et al.* PML/RARalpha targets promoter regions containing PU.1 consensus and
539 RARE half sites in acute promyelocytic leukemia. *Cancer Cell* **17**, 186–97 (2010).
- 540 52. Liu, N. *et al.* Direct Promoter Repression by BCL11A Controls the Fetal to Adult
541 Hemoglobin Switch. *Cell* **173**, 430–442.e17 (2018).
- 542 53. Li, B., Tournier, C., Davis, R. J. & Flavell, R. A. Regulation of IL-4 expression by the
543 transcription factor JunB during T helper cell differentiation. *EMBO J.* **18**, 420–432 (1999).
- 544 54. Schütte, J. *et al.* jun-B inhibits and c-fos stimulates the transforming and trans-activating
545 activities of c-jun. *Cell* **59**, 987–997 (1989).
- 546 55. Chiu, R., Angel, P. & Karin, M. Jun-B differs in its biological properties from, and is a
547 negative regulator of, c-Jun. *Cell* **59**, 979–986 (1989).
- 548 56. Descombes, P. & Schibler, U. A liver-enriched transcriptional activator protein, LAP, and
549 a transcriptional inhibitory protein, LIP, are translated from the same mRNA. *Cell* **67**, 569–
550 579 (1991).
- 551 57. Bedi, R., Du, J., Sharma, A. K., Gomes, I. & Ackerman, S. J. Human C/EBP- ϵ activator
552 and repressor isoforms differentially reprogram myeloid lineage commitment and
553 differentiation. *Blood* **113**, 317–327 (2009).
- 554 58. Meyers, R. M. *et al.* Computational correction of copy number effect improves specificity
555 of CRISPR-Cas9 essentiality screens in cancer cells. *Nat. Genet.* **49**, 1779–1784 (2017).
- 556 59. Postigo, A. A. & Dean, D. C. Differential expression and function of members of the zfh-1
557 family of zinc finger/homeodomain repressors. *Proc. Natl. Acad. Sci.* **97**, 6391–6396

- 558 (2000).
- 559 60. Sleven, H. *et al.* De Novo Mutations in EBF3 Cause a Neurodevelopmental Syndrome.
560 *Am. J. Hum. Genet.* **100**, 138–150 (2017).
- 561 61. Chao, H.-T. *et al.* A Syndromic Neurodevelopmental Disorder Caused by De Novo
562 Variants in EBF3. *Am. J. Hum. Genet.* **100**, 128–137 (2017).
- 563 62. Harms, F. L. *et al.* Mutations in EBF3 Disturb Transcriptional Profiles and Cause
564 Intellectual Disability, Ataxia, and Facial Dysmorphism. *Am. J. Hum. Genet.* **100**, 117–
565 127 (2017).
- 566 63. Pabst, T. *et al.* Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer
567 binding protein- α (C/EBP α), in acute myeloid leukemia. *Nat. Genet.* **27**, 263–270 (2001).
- 568 64. Ji, X. *et al.* Chromatin proteomic profiling reveals novel proteins associated with histone-
569 marked genomic regions. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 3841–6 (2015).
- 570 65. Villaseñor, R. *et al.* ChromID identifies the protein interactome at chromatin marks. *Nat.*
571 *Biotechnol.* (2020). doi:10.1038/s41587-020-0434-2
- 572 66. Gauchier, M., van Mierlo, G., Vermeulen, M. & Déjardin, J. Purification and enrichment of
573 specific chromatin loci. *Nat. Methods* **17**, 380–389 (2020).
- 574
- 575
- 576

577 **Figure Legends**

578

579 **Fig. 1. Transposase/peroxidase fusion probes tag DNA at regions of open chromatin.** (a)
580 Schematic of integrative DNA And Protein Tagging (iDAPT). TP, transposase/peroxidase fusion
581 protein. (b) Integrative Genomics Viewer (IGV) genome track view of ATAC-seq (Nextera Tn5,
582 Tn5-F) and iDAPT-seq (TP3, TP5) libraries at a ubiquitously accessible control region. Libraries
583 were generated from the GM12878 cell line. (c) Scatterplots comparing genome-wide
584 transposon insertion frequencies of Nextera Tn5 (ATAC-seq) with either in-house Tn5-F (ATAC-
585 seq) or the transposase/peroxidase fusion TP3 (iDAPT-seq) in the GM12878 cell line. Pearson
586 correlation coefficients are displayed inline. (d) Distribution of Pearson correlation coefficients
587 between TP3 or Tn5-F ATAC-seq and co-immunostaining of markers of active chromatin (RNA
588 Pol II S2P, H3K27Ac) or repressive chromatin (H3K9me3) per nucleus in the HT1080 cell line.
589 Numbers of nuclei assessed per marker are displayed inline, with images obtained from a single
590 experiment. Center line, median value; box limits, upper and lower quartiles; whiskers, 1.5x
591 interquartile range; points, outliers. p-values, two-sided Wilcoxon rank-sum test with Bonferroni
592 correction. (e) Representative images of co-immunofluorescence staining of chromatin state
593 markers with TP3 ATAC-seq in the HT1080 cell line. Similar results were visually confirmed for
594 more than ten nuclei for each chromatin marker and are quantified in (d). Scale bars, 5 μ m.

595

596 **Fig. 2. iDAPT-MS reveals the open chromatin-associated proteome.** (a) Schematic of
597 iDAPT-MS experimental design and SL-TMT sample labeling for K562 profiling. (b) Volcano plot
598 of proteins enriched by fusion (TP3 and TP5) versus negative control (Tn5-F and APEX2-F)
599 probes in K562 nuclei. Blue points, \log_2 fold change > 0 and false discovery rate (FDR) $< 5\%$;
600 red points, CisBP sequence-specific transcription factors; black points, points with
601 corresponding gene symbol labels. (c) IGV genome track view of iDAPT-seq (TP3) libraries
602 generated from either intact nuclei or genomic DNA from K562 cells and CUT&RUN libraries
603 from K562 nuclei using ERH, WBP11, or normal rabbit IgG antibodies. (d) Representative
604 images of co-immunofluorescence staining of the SC35 nuclear speckle marker with Tn5-F
605 ATAC-seq in the HT1080 cell line. Similar results were visually confirmed for more than ten
606 nuclei for each chromatin marker and are quantified in **Extended Data Fig. 6c**. Scale bars, 5
607 μ m. (e and f) Mediator (e) and BAF (f) CORUM complex enrichment by iDAPT-MS with fusion
608 probes in both K562 and NB4 cell lines. NES (normalized enrichment score) and p-value, gene
609 set enrichment analysis. Legend, individual protein-level iDAPT-MS enrichment. (g) MAX
610 BioGrid first-order protein interaction network enrichment by iDAPT-MS with fusion probes in the

611 K562 cell line. NES (normalized enrichment score) and p-value, gene set enrichment analysis.
612 Legend, individual protein-level iDAPT-MS enrichment. (h) Distribution of Jaccard indices
613 between MAX ChIP-seq peaks and ChIP-seq peaks of first-order protein interactors within
614 regions of open chromatin in the K562 cell line. MAX ChIP 1, ENCFF618VMC. MAX ChIP 2,
615 ENCFF900NVQ. BG, background ChIP-seq epitopes, collated from ENCODE K562 ChIP-seq
616 datasets of proteins not annotated to interact with MAX by BioGrid. Center line, median value;
617 box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; black points, outliers.
618 Red point, replicate MAX ChIP-seq epitope. p-values, two-sided Wilcoxon rank-sum test. n ,
619 number of represented ChIP-seq epitopes.

620

621 **Fig. 3. Integrative analysis of iDAPT-MS and iDAPT-seq classifies transcription factor**
622 **activities on open chromatin at steady state.** (a) Enrichment of CisBP sequence-specific
623 transcription factors via K562 iDAPT-MS. Normalized enrichment score (NES) and p-value,
624 gene set enrichment analysis. (b) Schematic of bivariate footprinting analysis of iDAPT-seq data.
625 FPD, footprint depth. FA, flanking accessibility. (c) Bivariate footprinting analysis of native
626 chromatin versus naked genomic DNA from the K562 cell line. Red, class A transcription
627 factors; blue, class B transcription factors; gray, class C transcription factors. (d-f) K562
628 genome-wide footprint of CTCF (d, class A), RELA/p65 (e, class B), and IKZF1 (f, class C) from
629 native chromatin (red) and naked DNA (black). Corresponding iDAPT-MS and ENCODE ChIP-
630 seq enrichment metrics are listed below. iDAPT-MS LFC, log₂ fold change; FDR, limma false
631 discovery rate. ChIP-seq NES, normalized enrichment score; p, gene set enrichment analysis p-
632 value. (g) Comparison of CisBP sequence-specific transcription factors enriched by iDAPT-MS
633 versus iDAPT-seq footprinting analysis in the K562 cell line. (h) Number of significant CisBP
634 transcription factors in each footprinting class as determined by iDAPT-MS or ENCODE ChIP-
635 seq, with corresponding numbers of associated transcription factor motifs per class as
636 determined by iDAPT-seq.

637

638 **Fig. 4. iDAPT profiling of the NB4 acute promyelocytic leukemia cell line upon all-*trans***
639 **retinoic acid (ATRA) treatment reveals dynamics of transcription factor activity.** (a)
640 Schematic of the consequences of PML-RARA fusion oncogene on hematopoiesis and relief of
641 its differentiation blockade by ATRA treatment. (b) Representative flow cytometry plots of NB4
642 cells treated with or without ATRA after 48 hrs. (c) Comparison of CisBP sequence-specific
643 transcription factor enrichment by TP3 iDAPT-MS (log₂ fold change) versus iDAPT-seq
644 footprinting analysis (composite footprinting score) in the NB4 cell line upon treatment with

645 either ATRA or DMSO. Roman numerals, transcription factor classification as described in
646 **Extended Data Fig. 10a.** (d-g) PU.1/SPI1 and BCL11A BioGrid first-order protein interaction
647 networks (d and f) and corresponding genome-wide motif footprints (e and g) upon treatment
648 with either ATRA (red) or DMSO (black) in the NB4 cell line. NES (normalized enrichment
649 score) and p-value, gene set enrichment analysis. Legend, individual protein-level iDAPT-MS
650 enrichment. (h) Assessment of NB4 cell line-specific genetic dependencies versus NB4 iDAPT-
651 MS negative enrichment upon ATRA treatment. Dependency scores are as reported from the
652 CRISPR (Avana) 19Q3 dataset.

653

654

655 **Online Methods**

656 Additional information may be found in the Life Sciences Reporting Summary.

657

658 **Cell lines and culture conditions.** GM12878 cells (Coriell) were cultured in RPMI-1640
659 supplemented with L-glutamine (Gibco), 15% heat-inactivated fetal bovine serum (FBS) (Gibco),
660 and 1% penicillin/streptomycin (Thermo Fisher Scientific). HT1080 (American Type Culture
661 Collection, ATCC) were cultured in EMEM (ATCC) supplemented with 10% FBS and 1%
662 penicillin/streptomycin. MDA-MB-231 (ATCC) and HEK293T (ATCC) cells were maintained in
663 DMEM (Gibco) supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin.
664 DU145 (ATCC) and K562 (ATCC) cells were cultured in RPMI-1640 supplemented with 10%
665 FBS and 1% penicillin/streptomycin. NB4 cells (DSMZ) were cultured in RPMI-1640
666 supplemented with 10% charcoal-stripped FBS (Gibco) and 1% penicillin/streptomycin. *All-trans*
667 retinoic acid (ATRA, Sigma) was dissolved in DMSO at a concentration of 10 mM. Cells were
668 incubated at 37 °C and 5% CO₂. Genomic DNA was extracted from K562 and NB4 cells using
669 the Quick-DNA MiniPrep kit (Zymo).

670

671 **Cloning and purification of recombinant proteins.** Expression plasmids were acquired
672 (pTXB1-Tn5, Addgene #60240) or cloned (APEX2 ORF from pTRC-APEX2, Addgene #72558)
673 into the pTXB1 vector (NEB). Fusion constructs with different peptide linkers⁶⁷ were generated
674 by site-directed mutagenesis (NEB). Plasmids containing C-terminally tagged gene constructs
675 as described in this study are deposited to Addgene (#160081, #160083-160088). All enzymes
676 were expressed and purified similarly as previously described⁶⁸. In brief, plasmids were
677 transformed into the Rosetta2 E. coli strain (EMD Millipore) and streaked out on an LB agar
678 plate containing ampicillin and chloramphenicol. A single bacterial colony was inoculated into 10
679 mL LB with antibiotics and incubated overnight; this culture was then inoculated into 500 mL LB
680 medium. Cultures were incubated at 37 °C until the optical density at 600 nm (OD₆₀₀) reached
681 ~0.9. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 250
682 μM, cultures were incubated for 2 h at 30 °C, and bacteria were pelleted and frozen at -80 °C.

683 Bacterial pellets were resuspended in 40 mL HEGX lysis buffer (20 mM HEPES-KOH pH 7.2,
684 1 M NaCl, 1 mM EDTA, 10% glycerol, 0.2% Triton X-100, 20 μM PMSF) and sonicated with a
685 Sonic Dismembrator 100 (Fisher Scientific) at setting 7, with 5 pulses of 30 s on/off on ice.
686 Lysate was spun at 15,000 x g in a Beckman centrifuge (JA-10 rotor) for 30 min at 4 °C. 1 mL
687 10% PEI was then added to the supernatant with agitation and clarified by centrifugation
688 (15,000 x g, 15 min, 4 °C). Supernatant was then applied to 5 mL chitin resin (NEB) prewashed

689 with HEGX buffer and incubated for 1 h at 4 °C with agitation. Chitin slurry was applied to an
690 Econo-Pak column (Bio-Rad) to remove unbound protein, washed with 20 column volumes of
691 HEGX buffer and 1 column volume of HEGX with 50 mM DTT, and then incubated with 1
692 column volume of HEGX with 50 mM DTT for 48 h at 4 °C. After elution, the column was
693 washed with 1 column volume of 2x dialysis buffer (2xDB: 100 mM HEPES-KOH pH 7.2, 0.2 M
694 NaCl, 0.2 mM EDTA, 20% glycerol, 0.2% Triton X-100, 2 mM DTT). Eluates were combined,
695 concentrated with a 10 kDa MWCO centrifugal filter (EMD Millipore), and subjected to buffer
696 exchange with 2xDB using PD-10 desalting columns (GE Healthcare). Proteins were quantified
697 via detergent-compatible Bradford assay (Thermo Fisher Scientific), snap frozen with liquid
698 nitrogen, and stored at -80 °C.

699

700 **Transposome adaptor preparation.** All transposome adaptors were synthesized at Thermo
701 Fisher Scientific. The oligonucleotide sequences were similar as previously described^{18,68}:
702 Tn5MErev, 5'-[phos]CTGTCTCTTATACACATCT-3'; Tn5ME-A, 5'-
703 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3'; Tn5ME-B: 5'-
704 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3'; Tn5ME-A-AF647, 5'-
705 /AlexaFluor647/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3'; Tn5ME-B-AF647: 5'-
706 /AlexaFluor647/GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3'. All oligos were
707 resuspended in water to a final concentration of 200 µM each. Equimolar amounts of
708 Tn5MErev/Tn5ME-A, Tn5MErev/Tn5ME-B, Tn5MErev/Tn5ME-A-AF647, and
709 Tn5MErev/Tn5ME-B-AF647 were added together in separate tubes, denatured at 95 °C for 10
710 min, and cooled slowly to room temperature by removing the heat block. Tn5MEDS-
711 A/Tn5MEDS-B and Tn5MEDS-A-AF647/Tn5MEDS-B-AF647 were combined at equimolar
712 amounts to form 100 µM stocks of Tn5MEDS-A/B and Tn5MEDS-A/B-AF647, aliquoted, and
713 stored at -20 °C.

714

715 **Electrophoretic mobility shift assay and DNA fragmentation analysis.** pSMART HCAmp
716 plasmid (Lucigen) was linearized with EcoRV-HF (NEB) and column-purified. DNA:protein
717 complexes were assembled by incubating 12 pmol enzyme in 2xDB buffer with 15 pmol MEDS-
718 A/B in water for 1 h at room temperature. 200 ng of linearized plasmid was then added to the
719 enzyme mix and brought to a final volume of 20 µL containing 20% dimethylformamide, 20 mM
720 Tris-HCl pH 7.5, and 10 mM MgCl₂, with or without 50 mM EDTA. Tagmentation reactions were
721 then incubated for 30 min at 37 °C. For gel shift analysis, reactions were subjected to
722 electrophoresis on a 1% agarose gel in Tris-acetate-EDTA (TAE) buffer using gel loading dye

723 without SDS (NEB). DNA fragmentation was assessed by adding SDS to a final concentration of
724 0.2% to the reaction mix after tagmentation and heating at 55 °C for 15 min. Reactions were
725 then subjected to electrophoresis on a 1% agarose gel cast in TAE and ethidium bromide using
726 gel loading dye with SDS (NEB). Images were acquired via a Gel Doc (Bio-Rad) via the
727 Quantity One v4.2.1 software.

728

729 **ATAC-seq/iDAPT-seq sample preparation.** The OmniATAC sample preparation protocol was
730 used as previously described with modifications where indicated below¹⁹. 10 pmol enzyme (2 µL
731 in 2xDB) was mixed with 12.5 pmol MEDS-A/B (1.25 µL in water) and incubated at room
732 temperature for 1 h. In the meantime, 50,000 cells were centrifuged at 500 x g for 5 min at 4°C.
733 Cells were resuspended in 50 µL lysis buffer 1 (LB1: 10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3
734 mM MgCl₂, 0.01% digitonin, 0.1% Tween-20, and 0.1% NP-40) with trituration, incubated on ice
735 for 3 min, and then further supplemented with 1 mL lysis buffer 2 (LB2: 10 mM Tris-HCl pH 7.5,
736 10 mM NaCl, 3 mM MgCl₂, and 0.1% Tween-20). Nuclei were pelleted (500 x g, 10 min, 4 °C),
737 resuspended with 50 µL tagmentation reaction mixture (20% dimethylformamide, 10 mM MgCl₂,
738 20 mM Tris-HCl pH 7.5, 33% 1xPBS, 0.01% digitonin, 0.1% Tween-20, and either 10 pmol
739 enzyme equivalent of enzyme:DNA complex or 2.5 µL Nextera Tn5 [Illumina, TDE1 from FC-
740 121-1030] in 50 µL total volume), and incubated at 37 °C for 30 min with agitation on a
741 thermomixer (1,000 rpm). For iDAPT-seq libraries generated from K562 or NB4 cells or genomic
742 DNA, bovine serum albumin (BSA) was added at a final concentration of 1% to lysis (LB1 and
743 LB2) and tagmentation buffers. Tagmentation with naked genomic DNA was performed using
744 50 ng genomic DNA as substrate. After tagmentation, DNA libraries were extracted with DNA
745 Clean and Concentrator-5 (Zymo) and eluted with 21 µL water.

746 To determine optimal PCR cycle number for library amplification, quantitative PCR was
747 performed similarly as previously reported on a StepOnePlus Real-Time PCR (Applied
748 Biosystems) with the StepOne v2.3 software⁸. 2 µL of each ATAC-seq or iDAPT-seq library was
749 added to 2x NEBNext Master Mix (NEB) and 0.4x SYBR Green (Thermo Fisher) with 1.25 µM of
750 each primer (Primer 1: 5'-
751 AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTCAGATGTG-3'; Primer 2.1:
752 5'-CAAGCAGAAGACGGCATAACGAGATTCGCCTTAGTCT CGTGGGCTCGGAGATGT-3') in a
753 final volume of 15 µL, and quantification was assessed using the following conditions: 72 °C for
754 5 min; 98 °C for 30 s; and thermocycling at 98 °C for 10 s, 63 °C for 30 s and 72 °C for 1 min.
755 Optimal PCR cycle number was determined as the qPCR cycle yielding fluorescence between
756 1/4 and 1/3 of the maximum fluorescence. The remaining DNA library was then amplified

757 accordingly by PCR using previously reported barcoded primers for library multiplexing⁸, purified
758 with DNA Clean and Concentrator-5 (Zymo), and eluted into 20 µL final volume with water.
759 Libraries were then subject to TapeStation 2200 High Sensitivity D1000 or D5000 fragment size
760 analysis (Agilent) and NextSeq 500 High Output paired-end sequencing (2x75 bp, Illumina) as
761 indicated.

762

763 **ATAC-seq/iDAPT-seq data preprocessing.** Paired-end sequencing reads were trimmed with
764 TrimGalore v0.4.5 to remove adaptor sequence CTGTCTCTTATACACATCT, which arises at
765 the 3' end due to sequenced DNA fragments being shorter than the sequencing length (75 bp).
766 Reads were aligned to the hg38 reference genome using bowtie2 v2.2.9 with options "--no-unal
767 --no-discordant --no-mixed -X 2000". Reads mapping to the mitochondrial genome were
768 subsequently removed, and duplicate reads were removed with Picard v2.8.0. For insert size
769 distribution, transcription start site (TSS) enrichment, and genome track visualization analyses,
770 reads were downsampled to approximately 5 million paired-end fragments. Insert size
771 distributions were determined by counting inferred fragment sizes from read alignments. TSS
772 enrichment was performed by first shifting insert positions aligned to the reverse strand by -5 bp
773 and the forward strand by +4 bp as previously described⁸ and then determining the distance of
774 each insertion to the closest Ensembl v94 transcription start site with Homer v4.9. Visualization
775 was performed by mapping insertions to a genome-wide sliding 150 bp window with 20 bp
776 offsets with bedops v2.4.30, followed by conversion to bigwig format with wigToBigWig from
777 UCSC tools v363. Genome tracks were visualized with Integrative Genomics Viewer v2.5.0.

778 Peaks were aligned by MACS2 v2.1.1 using options "callpeak --nomodel --shift -100 --
779 extsize 200 --nolambda -q 0.01 --keep-dup all", generating either individual peak sets from each
780 library (GM12878 analysis) or a consensus peak set after consolidating all reads (K562, NB4
781 analyses). For GM12878 analysis, a union of all analyzed peaks was taken as a consensus
782 peak set, and counts of insertions within peaks (downsampled to 5 million reads) were
783 assessed using bedtools v2.26.0 with the multicov function. Correlation analysis was performed
784 with log₂ read counts + 1 and visualized using the pheatmap function in R v3.5.0. For K562 and
785 NB4 analyses, consensus peaks overlapping with hg38 blacklist regions were removed
786 (<https://www.encodeproject.org/annotations/ENCSR636HFF/>), and counts of insertions within
787 peaks were assessed using the bedtools multicov function. Count matrices were processed with
788 DESeq2 for differential insertions with shrunken log₂ fold changes, and principal component
789 analyses were performed with counts transformed by the varianceStabilizingTransformation
790 function from DESeq2. Figures were generated with ggplot2 v3.1.1.

791

792 **Co-immunofluorescence/ATAC-see analysis.** ATAC-see was performed similarly as
793 previously described with slight modifications¹⁸. Enzyme and transposon DNA were mixed at a
794 1:1.25 enzyme:MEDS-A/B-AF647 molar ratio and incubated at room temperature for 1 h.
795 Adherent cells were grown on glass coverslips (Fisher Scientific, 12-540A) until 80-90%
796 confluent, washed with 1xPBS, fixed with 1% formaldehyde (Electron Microscopy Services) in
797 1xPBS for 10 min, and washed twice with ice-cold 1xPBS. Immobilized cells were lysed by
798 incubation with LB1 for 3 min followed by LB2 for 10 min at room temperature. Cells were then
799 subject to tagmentation (20% dimethylformamide, 10 mM MgCl₂, 20 mM Tris-HCl pH 7.5, 33%
800 1xPBS, 0.01% digitonin, 0.1% Tween-20, and 80 pmol enzyme equivalent of enzyme:DNA
801 complex in a total volume of 100 µL) for 30 min at 37 °C in a humidified chamber. Subsequently,
802 cells were washed with 50 mM EDTA and 0.01% SDS in 1xPBS three times for 15 min each at
803 55 °C, lysed for 10 min with 0.5% Triton X-100 in 1xPBS at room temperature, and blocked with
804 1% BSA and 10% goat serum in PBS-T (1xPBS and 0.1% Tween-20) for 1 h in a humidified
805 chamber. Primary antibody was added to slides in 1% BSA/PBS-T and incubated at 4 °C
806 overnight; slides were then washed and subjected to secondary antibody staining for 1 h. Slides
807 were washed with PBS-T three times for 15 min each, stained with DAPI (Sigma, 1 µg/mL) for 1
808 min, washed with PBS for 10 min, and mounted with Fluorescence Mounting Medium (Dako).
809 Confocal microscopy images were taken with an LSM 880 Axio Imager 2 or an LSM 880 Axio
810 Observer at 63x magnification (Zeiss). Images were processed with Fiji/ImageJ v2.0.0.

811 Primary antibodies used were anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2)
812 (rabbit, Abcam ab5095, 1:500), anti-H3K27Ac (rabbit, Abcam ab4729, 1:500), anti-H3K9me3
813 (rabbit, Abcam ab8898, 1:500), anti-SC35 (mouse, SC-35, Abcam ab11826, 1:1000).
814 Secondary antibodies used were Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor
815 488 conjugate (Thermo Fisher Scientific A11008, 1:1000) and Goat anti-Mouse IgG (H+L)
816 Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 conjugate (Thermo Fisher Scientific
817 A11001, 1:1000).

818 Quantitative image analyses were performed with CellProfiler v3.1.5. Region of interests
819 (ROIs) were identified from DAPI channel intensity values using minimum cross entropy
820 thresholding, with each ROI corresponding to an individual nucleus. Pearson correlation
821 coefficients were determined by comparing ATAC-see pixel intensities with corresponding
822 immunofluorescence intensity values within each ROI to assess the nucleus-to-nucleus
823 variation in colocalization.

824

825 **Peroxidase activity assay.** 5 pmol enzyme was incubated with 2.5 pmol hemin chloride
826 (Cayman Chemical, dissolved in DMSO) for 1 h at room temperature. This molar ratio was
827 selected given reports of APEX2 maximal heme occupancy between 40-57%. Heme:protein
828 complexes were then subjected to 50 μ M Amplex UltraRed (Thermo Fisher Scientific) and 1 mM
829 hydrogen peroxide for 1 min at room temperature in a total volume of 100 μ L with 1xPBS.
830 Reactions were then quenched with 100 μ L 2x quenching solution (10 mM Trolox, 20 mM
831 sodium ascorbate, and 20 mM NaN_3 in 1xPBS), and fluorescence intensities were measured on
832 a SpectraMax iD3 plate reader with the SoftMax Pro v7.0.3 software, with excitation at 530 nm
833 and emission at 590 nm.

834
835 **DNA and protein tagging by iDAPT.** All iDAPT proteomic labeling assays were performed as
836 described below unless indicated otherwise. 2.5 μ mol MEDS-A/B, 2 μ mol enzyme, and 1 μ mol
837 hemin chloride per channel were incubated at room temperature for 1 h. 1×10^7 cells per sample
838 were washed (500 x g, 5 min, 4 $^\circ\text{C}$), lysed and triturated in 100 μ L LB1 (10 mM Tris-HCl pH 7.5,
839 10 mM NaCl, 3 mM MgCl_2 , 1% BSA, 0.01% digitonin, 0.1% Tween-20, 0.1% NP-40, and 1x
840 cOmplete EDTA-free protease inhibitor cocktail [Roche]) for 3 min, and subsequently
841 supplemented with an additional 1 mL of LB2 (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM
842 MgCl_2 , 1% BSA, 0.1% Tween-20, and 1x protease inhibitor). Nuclei were pelleted (500 x g, 10
843 min, 4 $^\circ\text{C}$), resuspended with tagmentation reaction mixture (20% dimethylformamide, 10 mM
844 MgCl_2 , 20 mM Tris-HCl pH 7.5, 33% 1xPBS, 1% BSA, 0.01% digitonin, 0.1% Tween-20, 500 μ M
845 biotin-phenol, 1x protease inhibitor, and 2 μ mol enzyme equivalent of enzyme:DNA:heme
846 complex in a total volume of 500 μ L), and incubated at 37 $^\circ\text{C}$ for 30 min with agitation on a
847 thermomixer (1,000 rpm). 5 μ L of tagmentation mix was saved for quality assessment as
848 described above for ATAC-seq/iDAPT-seq sample preparation. The remaining nuclear
849 suspension was then washed 2x with 1xPBS supplemented with 500 μ M biotin-phenol, 1% BSA,
850 0.1% Tween-20, and 1x protease inhibitor (3000 x g, 5 min, 4 $^\circ\text{C}$) and labeled with 1 mM
851 hydrogen peroxide and 500 μ M biotin-phenol for 1 min in 1xPBS with 1x protease inhibitor in a
852 volume of 500 μ L. Peroxidation reactions were quenched with 500 μ L 2x quenching buffer (10
853 mM Trolox, 20 mM sodium ascorbate, 20 mM NaN_3 , and 1x protease inhibitor in 1xPBS).
854 Labeled nuclei were then pelleted, washed with 1x quenching buffer, resuspended in 500 μ L
855 RIPA containing protease inhibitors, and frozen at -80 $^\circ\text{C}$. Lysates were thawed on ice,
856 sonicated via a Sonic Dismembrator 100 (Fisher Scientific, setting 3, 15 s, 4 pulses), and
857 incubated on ice for 30 min after the addition of 1 μ L benzonase (EMD Millipore). Lysates were
858 clarified by centrifugation (15,000 x g, 20 min, 4 $^\circ\text{C}$), quantified via the detergent-compatible

859 Bradford assay (Thermo Fisher Scientific), and subjected to either Western blotting or
860 quantitative mass spectrometry analyses as described below. For NB4 cell analysis, an
861 additional endogenous peroxidase blocking step was added after nuclear extraction and before
862 tagmentation: nuclei were resuspended in 500 μ L 1xPBS containing 1% BSA, 0.03% hydrogen
863 peroxide, and 0.1% NaN₃ and incubated on ice for 30 min. Nuclei were pelleted and washed 4x
864 with 1xPBS/1% BSA (3000 x g, 5 min, 4 °C). Residual hydrogen peroxide was monitored by
865 colorimetric assessment of supernatant via Quantofix peroxides test stick (Sigma).

866

867 **Western blotting analysis.** Whole cell or nuclear lysates were generated by resuspending cells
868 or nuclei in RIPA (Boston BioProducts) supplemented with 1x cOmplete EDTA-free protease
869 inhibitor cocktail (Roche). Lysates were incubated on ice for 30 min, sonicated via a Sonic
870 Dismembrator 100 (Fisher Scientific) at setting 3 with 3-4 pulses of 15 s on/off on ice, and
871 treated with benzonase for an additional 30 min on ice. Lysates were clarified by centrifugation
872 (15,000 x g, 20 min, 4 °C) and their concentrations quantified via the detergent-compatible
873 Bradford assay (Thermo Fisher Scientific). All Western blots were run on NuPAGE 4-12% Bis-
874 Tris protein gels (Thermo Fisher Scientific) and transferred to 0.2 μ m nitrocellulose membranes
875 (GE Healthcare). Membranes were blocked with 3% milk in PBS-T and incubated overnight with
876 primary antibody and subsequently with secondary antibody after brief washing with PBS-T.
877 Chemiluminescence was determined by applying ECL Western Blotting detection reagent (GE
878 Healthcare) to membranes and imaging on an Amersham Imager 600 (GE Healthcare).
879 Membranes were stripped with Restore PLUS Stripping Buffer (Thermo Fisher Scientific).

880 Primary antibodies used were anti-FLAG M2 (mouse, Sigma-Aldrich, F1804, 1:2000), anti-
881 PCNA (mouse, PC10, Santa Cruz Biotechnology sc-56, 1:1000), and anti-PML (rabbit, Bethyl
882 A301-167A, 1:1000). Secondary antibodies used were Rabbit IgG, HRP-linked F(ab')₂ fragment
883 (GE Healthcare NA9340, from donkey, 1:5000) and Mouse IgG, HRP-linked whole Ab (GE
884 Healthcare NA931, from sheep, 1:5000). Streptavidin-HRP (Cell Signaling Technology #3999S,
885 1:1000) was also used for probing.

886

887 **Streptavidin enrichment and tandem mass tag labeling.** 250 μ g (K562) or 150 μ g (NB4)
888 lysate was reduced with 5 mM DTT and then added to 60 μ L (K562) or 90 μ L (NB4) Pierce
889 streptavidin bead slurry equilibrated 2x with RIPA buffer. Lysate/bead mixture was incubated
890 with end-to-end rotation overnight at 4 °C. Beads were washed 3x with RIPA, 2x with 200 mM
891 EPPS pH 8.5, and resuspended with 100 μ L 200 mM EPPS pH 8.5, with beads resuspended
892 and incubated with end-to-end rotation for 5 min per wash. 1 μ L mass spectrometry-grade LysC

893 (Wako) was added to each tube and incubated at 37 °C for 3 h with mixing, and an additional 1
894 µL mass spectrometry-grade trypsin (Thermo Fisher Scientific) was added, followed by
895 overnight incubation at 37 °C with mixing. Beads were magnetized, and eluate was collected
896 and subjected to downstream TMT labeling.

897 Peptides were processed using the SL-TMT method²⁴. TMT reagents (0.8 mg) were
898 dissolved in anhydrous acetonitrile (40 µL), of which 10 µL was added to each peptide
899 suspension (100 µL) with 30 µL of acetonitrile to achieve a final acetonitrile concentration of
900 approximately 30% (v/v). Following incubation at room temperature for 1 h, the reaction was
901 quenched with hydroxylamine to a final concentration of 0.3% (v/v). The TMT-labeled samples
902 were pooled at a 1:1 ratio across all samples. The pooled sample was vacuum centrifuged to
903 near dryness and subjected to C18 solid-phase extraction (SPE) (Sep-Pak, Waters).

904
905 **Off-line basic pH reversed-phase (BPRP) fractionation.** We fractionated the pooled TMT-
906 labeled peptide sample using BPRP HPLC⁶⁹. We used an Agilent 1200 pump equipped with a
907 degasser and a photodiode array (PDA) detector (set at 220 and 280 nm wavelength) from
908 ThermoFisher Scientific (Waltham, MA). Peptides were subjected to a 50-min linear gradient
909 from 9% to 35% acetonitrile in 10 mM ammonium bicarbonate pH 8 at a flow rate 600 µL/min
910 over an Agilent 300Extend C18 column (3.5 µm particles, 4.6 mm ID and 220 mm in length).
911 The peptide mixture was fractionated into a total of 96 fractions, which were consolidated into
912 24 super-fractions⁷⁰. Samples were subsequently acidified with 1% formic acid and vacuum
913 centrifuged to near dryness. Each consolidated fraction was desalted via StageTip, dried again
914 via vacuum centrifugation, and reconstituted in 5% acetonitrile, 5% formic acid for LC-MS/MS
915 processing.

916
917 **LC-MS/MS proteomic analysis.** Samples were analyzed on an Orbitrap Fusion mass
918 spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to a Proxeon EASY-nLC 1200
919 liquid chromatography (LC) pump (Thermo Fisher Scientific). Peptides were separated on a 100
920 µm inner diameter microcapillary column packed with 35 cm of Accucore C18 resin (2.6 µm,
921 150 Å, ThermoFisher). For each analysis, approximately 2 µg of peptides were separated using
922 a 150 min gradient of 8 to 28% acetonitrile in 0.125% formic acid at a flow rate of 450-500
923 nL/min. Each analysis used an MS3-based TMT method^{71,72}, which has been shown to reduce
924 ion interference compared to MS2 quantification⁷³. The scan sequence began with an MS1
925 spectrum (Orbitrap analysis, resolution 120,000, 350–1400 Th, automatic gain control (AGC)
926 target 2e5, maximum injection time 100 ms). The top ten precursors were then selected for

927 MS2/MS3 analysis. MS2 analysis consisted of: collision-induced dissociation (CID), quadrupole
928 ion trap analysis, automatic gain control (AGC) 1.4e4, NCE (normalized collision energy) 35, q-
929 value 0.25, maximum injection time 120 ms), and isolation window at 0.7. Following acquisition
930 of each MS2 spectrum, we collected an MS3 spectrum in which multiple MS2 fragment ions are
931 captured in the MS3 precursor population using isolation waveforms with multiple frequency
932 notches. MS3 precursors were fragmented by HCD and analyzed using the Orbitrap (NCE 65,
933 AGC 1.5e5, maximum injection time 150 ms, resolution was 50,000 at 400 Th).

934

935 **Proteomic data analysis.** Mass spectra were processed using a Sequest-based pipeline⁷⁴.
936 Spectra were converted to mzXML using a modified version of MSConvert. Database searching
937 included all entries from the human UniProt database. This database was concatenated with
938 one composed of all protein sequences in the reversed order. Searches were performed using a
939 50-ppm precursor ion tolerance for total protein level analysis. The product ion tolerance was
940 set to 0.9 Da. TMT tags on lysine residues and peptide N-termini (+229.163 Da) and
941 carbamidomethylation of cysteine residues (+57.021 Da) were set as static modifications, while
942 oxidation of methionine residues (+15.995 Da) was set as a variable modification.

943 Peptide-spectrum matches (PSMs) were adjusted to a 1% false discovery rate (FDR)^{75,76}.
944 PSM filtering was performed using a linear discriminant analysis (LDA), as described
945 previously⁷⁴, while considering the following parameters: XCorr, ΔC_n , missed cleavages,
946 peptide length, charge state, and precursor mass accuracy. For TMT-based reporter ion
947 quantitation, we extracted the summed signal-to-noise (S:N) ratio for each TMT channel and
948 found the closest matching centroid to the expected mass of the TMT reporter ion. PSMs with
949 poor quality, MS3 spectra with more than eight TMT reporter ion channels missing, MS3 spectra
950 with TMT reporter summed signal-to-noise of less than 100, missing MS3 spectra, or isolation
951 specificity < 0.7 were excluded from quantification⁷⁷.

952 PSM intensities were normalized by taking the median intensity of streptavidin and trypsin
953 PSMs per sample as a normalization factor, as these proteins are added to each sample in
954 equal amounts post-enrichment. Normalized PSMs were then log₂-transformed and collapsed
955 to proteins by arithmetic average, with priority given to uniquely mapping peptides. Hierarchical
956 clustering, Pearson correlation, and principal component analyses were performed at the
957 protein level. The limma package in R was used to determine differential protein abundances.

958

959 **Protein enrichment analyses.** Gene set enrichment analyses of iDAPT-MS datasets were
960 performed with the fgsea package (10,000 permutations) in R, using UniProt protein

961 identifications ranked by their log2 fold changes from limma⁷⁸. Gene sets used for analyses:
962 CORUM (v3.0) protein complex annotations³², Human Protein Atlas (v19) subcellular
963 localization annotations with reliability demarcated as “Enhanced” or “Supported”²⁷, BioGrid
964 (v3.5.178) multi-validated protein interaction annotations³⁵, ReactomeDB (v70) pathway to gene
965 mappings from fgsea via the “reactomePathways” function⁷⁹, and CisBP transcription factors
966 from the “human_pwm_v2” dataset curated as in the chromVARmotifs package in R^{36,47}. All
967 gene identities were converted to UniProt prior to analysis via biomaRt in R. Protein interaction
968 networks were visualized with igraph v1.2.4.

969 Four classes of nuclear proteins were collated: histones, chromatin remodelers, transcription
970 factors, and RNA-binding proteins. Histone UniProt IDs were collated from Histone DB 2.0⁸⁰ and
971 UniProt with search query “Nucleosome core”⁸¹. Chromatin remodeler proteins were obtained
972 from UniProt IDs associated with “GO:0006338” (“chromatin remodeling”)⁸² and CORUM protein
973 complex components associated with the five primary chromatin remodelers³²: NuRD, SWI,
974 ISWI, INO80, SWR1. High-confidence RNA binding proteins were obtained from hRBPome⁸³,
975 and transcription factors were obtained from Lambert et al.³.

976 K562 RNA-seq²⁵ (ENCFF664LYH and ENCFF855OAF), whole cell proteome³³, and nuclear
977 proteome³⁴ datasets were downloaded and converted to UniProt IDs. RNA-seq genes were
978 filtered for those with nonzero read counts (transcripts per million) in both replicates²⁵. The
979 whole cell proteomic dataset was filtered by removing peptides with missing quantitations³³. The
980 nuclear proteome dataset was preprocessed by removing peptides with multiple UniProt IDs
981 and collating remaining UniProt IDs across all salt extraction conditions³⁴. For determination of
982 proteins associated with specific extraction conditions, we followed a procedure as reported by
983 Federation et al.: peptide intensities were normalized by total intensities for a given sample,
984 collapsed to protein intensities by arithmetic mean, scaled to maximum intensities of 1, and
985 subjected to k-means clustering analysis using $k = 8$ for clustering³⁴. Protein annotations from
986 Alajem et al. were converted from mouse to human homologs via biomaRt in R, and gene sets
987 (1000U, 45U, 3U) were compiled taking the sets of protein IDs with scores greater than 95 in
988 either ES or NPC sample types¹³. Additional publicly available open chromatin proteome
989 datasets were downloaded, and gene identities were converted to UniProt IDs^{12,14}. Because
990 published datasets differ in their analytical depths from our iDAPT-MS datasets, we converted
991 gene identifiers to Human Protein Atlas subcellular enrichment proportions for better
992 comparison. Specifically, the proportion for each subcellular localization term and for each
993 dataset was calculated as the *(number of proteins overlapping between the subcellular term and*
994 *the dataset) / (number of proteins overlapping between all annotated Human Protein Atlas*

995 *proteins and the dataset*). These proportions were used as features for principal component
996 analysis.

997

998 **CUT&RUN sample preparation.** pAG/MNase (Addgene #123461) was expressed in Rosetta2
999 cells (EMD Millipore), purified with the Pierce His Protein Interaction Pull-Down kit (Thermo),
1000 and stored at either -80 °C for long-term storage or -20 °C for working stocks⁸⁴. CUT&RUN was
1001 performed similarly as previously reported²⁶. 500,000 K562 cells per assay were washed three
1002 times (room temperature, 3 min, 600 x g) in wash buffer (20 mM HEPES pH 7.5, 150 mM NaCl,
1003 0.5 mM spermidine, and 1x cOmplete EDTA-free protease inhibitor cocktail [Roche]).
1004 Concavalin A beads were activated by washing beads in binding buffer (20 µM HEPES pH 7.5,
1005 10 mM KCl, 1 mM CaCl₂, 1 mM MnCl₂). 10 µL activated Concavalin A beads were added to 100
1006 µL cell suspension and incubated with rotation for 10 min at room temperature. Supernatant
1007 was removed, and 100 µL wash buffer containing 0.01% digitonin (dig-wash buffer) was added.
1008 Antibodies were added at 1:50 concentration, and tubes were incubated with rotation overnight
1009 at 4 °C. Beads were washed with dig-wash buffer, pAG/MNase was added at a final
1010 concentration of 2 µg/mL, and suspensions were incubated for 1 h at 4 °C. Beads were further
1011 washed with wash buffer, resuspended in 100 µL wash buffer, and chilled to 0 °C in an ice-
1012 water bath. 2 µL 0.1 M CaCl₂ was added to each tube, and tubes were incubated for 1 h at 0 °C.
1013 100 µL stop buffer (340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 0.05% digitonin, 100 µg/mL
1014 RNase A, 50 µg/mL GlycoBlue) was added, and tubes were incubated for 15 min 37 °C to
1015 release DNA fragments. Supernatant was collected, SDS (0.1% final) and proteinase K (250
1016 µg/mL final) were added to each 200 µL sample, and tubes were incubated for 1 h at 50 °C.
1017 DNA was isolated by phenol/chloroform extraction, and libraries were constructed using the
1018 NEBNext Ultra kit (NEB) as previously described⁵². Libraries were then subject to TapeStation
1019 2200 High Sensitivity D1000 fragment size analysis (Agilent) and NextSeq 500 High Output
1020 paired-end sequencing (2x42 bp, Illumina). Primary antibodies used for CUT&RUN were: ERH
1021 (Bethyl, A305-402A; 1:50), WBP11 (Bethyl, A304-855A; 1:50), and normal rabbit IgG (EMD
1022 Millipore, #12-370; 1:50).

1023 Antibodies used for CUT&RUN were validated by immunoprecipitation followed by Western
1024 blotting analysis. K562 cells were lysed in RIPA, and 1.5 µL antibody was added to 500 µg
1025 protein lysate and incubated overnight at 4 °C. The next day, lysates were incubated with 20 µL
1026 Pierce protein A magnetic beads (Thermo) for 2 h at 4 °C, beads were washed in RIPA buffer,
1027 and bound protein was boiled in 2x LDS sample buffer for 10 min. Resulting protein lysates
1028 were subjected to Western blotting analysis as described above. Primary antibodies used for

1029 Western blotting were: ERH (Atlas Antibodies, HPA002567; 1:1,000) and WBP11 (Bethyl, A304-
1030 857A; 1:1,000).

1031

1032 **CUT&RUN analysis.** Paired-end sequencing reads were trimmed with TrimGalore v0.4.5 to
1033 remove adaptor sequence GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT with additional
1034 removal of fragments smaller than 25 bp. Reads were aligned to the hg38 reference genome
1035 using bowtie2 v2.2.9 with options "--no-unal --no-discordant --no-mixed --dovetail -l 25 -X 700".
1036 Reads mapping to the mitochondrial genome were subsequently removed, and duplicate reads
1037 were removed with Picard v2.8.0. Reads smaller than 120 bp were retained for subsequent
1038 analysis. Visualization was performed by mapping insertions to a genome-wide sliding 150 bp
1039 window with 20 bp offsets with bedops v2.4.30, followed by conversion to bigwig format with
1040 wigToBigWig from UCSC tools v363. Genome tracks were visualized with Integrative Genomics
1041 Viewer v2.5.0. Open chromatin regions were defined as 1% FDR-thresholded MACS2 peaks
1042 obtained from K562 iDAPT-seq relative to genomic DNA input as described above. CUT&RUN
1043 signal was determined relative to these peak regions and normalized by the signal intensity
1044 between +1950 and +2000 bp distal to the peak summit, representing background enrichment.
1045 CUT&RUN peaks were called by MACS2 v2.1.1 using options "callpeak -q 0.01 --keep-dup all".
1046 CUT&RUN and ChIP-seq peak overlap analyses were performed with bedtools v2.26.0 using
1047 the intersect function.

1048

1049 **ATAC-seq/iDAPT-seq transcription factor analysis.** Motif enrichment analysis was
1050 performed with ChromVAR as previously described using the human_pwms_v2 set of curated
1051 CisBP transcription factor motifs^{36,47}. ChromVAR motif deviations from the computeDeviations
1052 function were used for principal component analysis, and FDR-adjusted p-values were obtained
1053 with the differentialDeviations function with default settings.

1054 Bivariate footprinting analysis was performed similarly as previously described with slight
1055 modifications^{10,85}. CisBP motifs curated from the ChromVAR human_pwms_v2 dataset^{36,47} or
1056 motifs for ZEB2⁸⁶ and EBF3⁸⁷ were matched within peaks using matchMotifs from motifmatchr in
1057 R. Motif alignments were extended by 250 bp on each side, and adjusted transposon insertions
1058 were mapped to the corresponding regions. Motif flank height was determined by the average
1059 insertion rate between positions +1 to +50 bp, immediately flanking the motif. Background
1060 insertions were determined by the average insertion rate between positions +200 to +250 bp,
1061 distal to the positioned motif. Footprint height was determined by the 10% trimmed mean of the
1062 insertion rate within the 10-11 bp positioned around the center of the motif. Footprint depth

1063 (FPD) was determined as the log₂ count ratio of footprint height over flank height; flanking
1064 accessibility (FA) was determined as the log₂ count ratio of flank height over background. The
1065 norm of the orthogonal projection of FA and FPD scores onto the -45° line was used as a raw
1066 footprinting score. A linear regression model was implemented (*footprinting score* ~ *transcription*
1067 *factor* + *transcription factor:treatment*), from which the t-statistic of the interaction term per
1068 transcription factor motif (*transcription factor:treatment*) was used as the composite footprinting
1069 score, and the corresponding p-value, adjusted to false discovery rate with the Benjamini-
1070 Hochberg method, was used to assess significance.

1071 For analysis of transcription factor activity at steady-state, composite footprinting scores
1072 were modeled by a two-state Gaussian mixture model with mixtools in R, and class A
1073 footprinted motifs (strong footprinting) were determined to be those with greater than 50%
1074 probability of being in the Gaussian distribution further away from the origin. Class C footprinted
1075 motifs (no/negative footprinting) were determined as those with weak statistical significance
1076 (FDR > 5%) or negative enrichment (composite footprinting score < 0). Positive and significant
1077 footprinted motifs not in class A were demarcated as class B footprinted motifs (weak
1078 footprinting). Consensus transcription factor classifications were determined by concordance
1079 between K562 and NB4 steady-state footprinting analyses, limited to those transcription factors
1080 exhibiting positive significant enrichment from both corresponding iDAPT-MS datasets.

1081 For classification of transcription factors upon ATRA treatment, FDR < 5% thresholds of
1082 iDAPT-MS abundance and iDAPT-seq footprinting profiles were used to discriminate between
1083 classes.

1084

1085 **ChIP-seq analysis.** ENCODE ChIP-seq transcription factor datasets were downloaded from the
1086 ENCODE data portal²⁵ (<https://www.encodeproject.org/>). ENCODE K562 ChIP-seq datasets are
1087 listed in Supplementary Table 3. In brief, ChIP-seq bed files aligned to hg38 and annotated as
1088 “optimal IDR peaks” were downloaded, and iDAPT-seq peaks overlapping with ChIP-seq peaks
1089 were collated. ChIP-seq enrichment within open chromatin was determined by gene set
1090 enrichment analysis using iDAPT-seq differential peaks ranked by log₂ fold change using the
1091 fgsea package in R.

1092 Colocalization of ChIP-seq epitopes on open chromatin was determined using the Jaccard
1093 similarity coefficient, with colocalization determined if ChIP-seq peaks from different epitopes
1094 overlap a given iDAPT-seq peak.

1095

1096 **Granulocytic differentiation analysis.** NB4 cells treated either with DMSO or 1 μ M
1097 ATRA were washed with 2% fetal bovine serum prior to staining. Anti-human CD11b-PE-Cy7
1098 antibody conjugate (Clone: ICRF44, Biolegend Catalog #301321; 1:100) and anti-
1099 human CD11c-APC antibody conjugate (Clone: B-ly6, BD Pharmingen #559877; 1:100) were
1100 incubated with samples for 20 min and then washed to remove excess antibody. Stained
1101 samples were analyzed on a Beckman Coulter CytoFLEX LX flow cytometer with the
1102 CytoExpert v2.3.1.22 software. Data were analyzed with FlowJo v10.0.7.

1103

1104 **Cell proliferation assay.** NB4 cells were seeded at a density of 5×10^5 cells/mL subjected to
1105 either DMSO or 1 μ M ATRA. After 48 h, 50 μ L cell suspension was added to 50 μ L CellTiter-Glo
1106 reagent, incubated for 10 min at room temperature, and assayed for luminescence with a
1107 SpectraMax iD3 plate reader.

1108

1109 **Genetic dependency analysis.** Genetic dependency map (DepMap) scores generated from
1110 CRISPR/Cas9 pooled screening (Avena) were downloaded (19Q3, <https://depmap.org/portal/>).
1111 DepMap scores from hematopoietic cancer cell lines were collated, and the distribution of
1112 dependency scores was modeled as a two-state Gaussian mixture model with mixtools in R.
1113 Gene dependency was determined as the threshold corresponding to 50% probability of being
1114 in either distribution. Essential genes across hematopoietic cell lines were those genes
1115 representing dependencies across at least 50% of profiled hematopoietic cell lines.

1116

1117 **RNA-seq analysis.** Raw sequencing reads (GSM1288651, GSM1288652, GSM1288653,
1118 GSM1288654, GSM1288659, GSM1288660, GSM1288661, GSM1288662, GSM2464389,
1119 GSM2464392) were aligned to a reference transcriptome generated from the Ensembl v94
1120 database with salmon v0.14.1 using options "--seqBias --useVBOpt --gcBias --posBias --
1121 numBootstraps 30 --validateMappings". Length-scaled transcripts per million were acquired
1122 using the tximport function, and log₂ fold changes and false discovery rates were determined by
1123 DESeq2 in R, with batch as a covariate. Principal component analysis was performed with
1124 counts transformed by the varianceStabilizingTransformation function from DESeq2, and
1125 shrunken log₂ fold changes were determined with DESeq2, which were used to rank genes for
1126 gene set enrichment analysis. For comparison of RNA-seq and mass spectrometry datasets,
1127 gene symbols and Ensembl gene IDs were matched to UniProt IDs via biomaRt.

1128

1129 **Statistical analysis.** No statistical methods were used to predetermine sample size. The
1130 experiments were not randomized. The investigators were not blinded to allocation during
1131 experiments and outcome assessment. All statistical analyses were performed in R⁸⁸. Two-
1132 tailed statistical tests were used unless stated otherwise. Multiple comparison adjustments were
1133 performed as noted.

1134

1135 **Data availability.** iDAPT-seq/ATAC-seq and CUT&RUN datasets are deposited in GEO
1136 (GSE158350). iDAPT-MS proteomics data are deposited to the ProteomeXchange Consortium
1137 via the PRIDE partner repository (PXD022252). Raw confocal image files (.czi) are deposited to
1138 the Dryad repository at <https://doi.org/10.5061/dryad.4xgxd257p>.

1139 Raw iDAPT-seq/ATAC-seq sequencing data (GSE158350,
1140 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158350>) are associated with the
1141 following figures: **Fig 1b-c** and **Extended Data Fig 2** (GM12878 ATAC-seq, iDAPT-seq); **Fig**
1142 **2g-h, Fig 3,** and **Extended Data Figs 5, 7-8** (K562 iDAPT-seq); **Fig 4g, Extended Data Figs 7-**
1143 **8,** and **Supplementary Figs 5-9** (NB4 iDAPT-seq). Raw CUT&RUN sequencing data
1144 (GSE158350, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158350>) are associated
1145 with the following figures: **Fig. 2c** and **Extended Data Fig 5**. Raw mass spectrometry data
1146 (PXD022252, <https://www.ebi.ac.uk/pride/archive/projects/PXD022252>) are associated with the
1147 following figures: **Fig 2, Fig 3, Extended Data Figs. 3, 6, 8,** and **Supplementary Figs 3-4**
1148 **(K562 iDAPT-MS); Fig 4, Extended Data Figs. 4, 6, 8-10,** and **Supplementary Figs. 4, 6-10**
1149 **(NB4 iDAPT-MS)**. Preprocessed mass spectrometry data are available as supplementary tables
1150 (Supplementary Tables 1-2). Raw confocal microscopy image data
1151 (<https://doi.org/10.5061/dryad.4xgxd257p>) are associated with the following figures: **Fig 1d-e,**
1152 **2d,** and **Extended Data 6d-e**.

1153 Publicly available sequencing datasets used are as follows: GM12878 ATAC-seq:
1154 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47753> (SRR891268, SRR891269,
1155 SRR891270, SRR891271), <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA482539>
1156 (SRR7586167, SRR7586168), <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA305986>
1157 (SRR2999312, SRR2999313, SRR2999314, SRR2999315),
1158 <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA380283> (SRR5427884, SRR5427885,
1159 SRR5427886, SRR5427887); ENCODE K562 ChIP-seq: <https://www.encodeproject.org/>, with
1160 unique identifiers listed in Supplementary Table 3; ENCODE K562 RNA-seq:
1161 <https://www.encodeproject.org/files/ENCFF664LYH/@@download/ENCFF664LYH.tsv> and
1162 <https://www.encodeproject.org/files/ENCFF855OAF/@@download/ENCFF855OAF.tsv>; NB4 +/-

1163 ATRA RNA-seq: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53258>
1164 (GSM1288651, GSM1288652, GSM1288653, GSM1288654),
1165 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53259> (GSM1288659, GSM1288660,
1166 GSM1288661, GSM1288662), and
1167 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93877> (GSM2464389, GSM2464392).
1168 Publicly available proteome datasets used are as follows: whole cell proteome:
1169 https://gygi.med.harvard.edu/sites/gygi.med.harvard.edu/files/documents/protein_quant_current
1170 [_normalized.csv.gz](https://ars.els-cdn.com/content/image/1-s2.0-S2211124720301303-mmc2.xlsx); nuclear proteome and differential salt fractionation: [https://ars.els-](https://ars.els-cdn.com/content/image/1-s2.0-S2211124720301303-mmc2.xlsx)
1171 [cdn.com/content/image/1-s2.0-S2211124720301303-mmc2.xlsx](https://ars.els-cdn.com/content/image/1-s2.0-S2211124720301303-mmc2.xlsx), Alajem et al.:
1172 <https://www.cell.com/cms/10.1016/j.celrep.2015.02.064/attachment/daebc867-0c82-45ef-837b->
1173 [b408682c76cf/mmc2.xlsx](https://www.cell.com/cms/10.1016/j.celrep.2015.02.064/attachment/daebc867-0c82-45ef-837b-b408682c76cf/mmc2.xlsx); Torrente et al.: <https://doi.org/10.1371/journal.pone.0024747.s004>
1174 and <https://doi.org/10.1371/journal.pone.0024747.s006>; Kulej et al.:
1175 https://www.mcponline.org/highwire/filestream/35613/field_highwire_adjunct_files/5/TABLE_S5_
1176 [Host_chromatin_bound_proteome.xlsx](https://www.mcponline.org/highwire/filestream/35613/field_highwire_adjunct_files/5/TABLE_S5-Host_chromatin_bound_proteome.xlsx).
1177 Additional public reference datasets are as follows: hg38 reference genome:
1178 [ftp://ftp.ensembl.org/pub/release-](ftp://ftp.ensembl.org/pub/release-94/fasta/homo_sapiens/dna/Homo_sapiens.GRCh38.dna.primary_assembly.fa.gz)
1179 [94/fasta/homo_sapiens/dna/Homo_sapiens.GRCh38.dna.primary_assembly.fa.gz](ftp://ftp.ensembl.org/pub/release-94/fasta/homo_sapiens/dna/Homo_sapiens.GRCh38.dna.primary_assembly.fa.gz); hg38
1180 blacklist regions:
1181 <https://www.encodeproject.org/files/ENCFF356LFX/@@download/ENCFF356LFX.bed.gz>;
1182 CORUM v3.0 complexes: [http://mips.helmholtz-](http://mips.helmholtz-muenchen.de/corum/download/allComplexes.txt.zip)
1183 [muenchen.de/corum/download/allComplexes.txt.zip](http://mips.helmholtz-muenchen.de/corum/download/allComplexes.txt.zip); Human Protein Atlas v19:
1184 https://www.proteinatlas.org/download/subcellular_location.tsv.zip; BioGrid v3.5.178:
1185 [https://downloads.thebiogrid.org/File/BioGRID/Release-Archive/BIOGRID-3.5.178/BIOGRID-](https://downloads.thebiogrid.org/File/BioGRID/Release-Archive/BIOGRID-3.5.178/BIOGRID-MV-Physical-3.5.178.tab2.zip)
1186 [MV-Physical-3.5.178.tab2.zip](https://downloads.thebiogrid.org/File/BioGRID/Release-Archive/BIOGRID-3.5.178/BIOGRID-MV-Physical-3.5.178.tab2.zip); Lambert et al. transcription factors:
1187 [https://www.cell.com/cms/10.1016/j.cell.2018.01.029/attachment/ede37821-fd6f-41b7-9a0e-](https://www.cell.com/cms/10.1016/j.cell.2018.01.029/attachment/ede37821-fd6f-41b7-9a0e-9d5410855ae6/mmc2.xlsx)
1188 [9d5410855ae6/mmc2.xlsx](https://www.cell.com/cms/10.1016/j.cell.2018.01.029/attachment/ede37821-fd6f-41b7-9a0e-9d5410855ae6/mmc2.xlsx); HistoneDB 2.0:
1189 <https://www.ncbi.nlm.nih.gov/research/HistoneDB2.0/HistoneDB/static/browse/dumps/seqs.txt>;
1190 hRBPome: http://caps.ncbs.res.in/hrbpome/downloads/high_confidence_proteins.fasta;
1191 DepMap 19Q3: <https://ndownloader.figshare.com/files/16757666>. CisBP transcription factors
1192 (<http://cisbp.cbr.utoronto.ca/>) were obtained via the command `data("human_pwmms_v2")` in R
1193 package "chromVARmotifs": <https://github.com/GreenleafLab/chromVARmotifs>. ReactomeDB
1194 v70 pathway annotations (<https://reactome.org/>) were obtained via the "reactomePathways"
1195 command in R package "fgsea": <https://bioconductor.org/packages/release/bioc/html/fgsea.html>.
1196 Gene Ontology (<http://geneontology.org/>) was queried from org.Hs.eg.db using the "select"

1197 function from AnnotationDbi in R. UniProt IDs (<https://www.uniprot.org/>) were either downloaded
1198 from the UniProt website or collated via biomaRt in R
1199 (<https://www.bioconductor.org/packages/release/bioc/html/biomaRt.html>).

1200

1201 **Code availability.** R code used in this manuscript is deposited at
1202 <https://github.com/jonathandlee12/iDAPT-MS>.

1203

1204

1205 **Methods-Only References**

1206

- 1207 67. Chen, X., Zaro, J. L. & Shen, W.-C. Fusion protein linkers: property, design and
1208 functionality. *Adv. Drug Deliv. Rev.* **65**, 1357–69 (2013).
- 1209 68. Picelli, S. *et al.* Tn5 transposase and tagmentation procedures for massively scaled
1210 sequencing projects. *Genome Res.* **24**, 2033–2040 (2014).
- 1211 69. Wang, Y. *et al.* Reversed-phase chromatography with multiple fraction concatenation
1212 strategy for proteome profiling of human MCF10A cells. *Proteomics* **11**, 2019–26 (2011).
- 1213 70. Paulo, J. A. *et al.* Quantitative mass spectrometry-based multiplexing compares the
1214 abundance of 5000 *S. cerevisiae* proteins across 10 carbon sources. *J. Proteomics* **148**,
1215 85–93 (2016).
- 1216 71. Ting, L., Rad, R., Gygi, S. P. & Haas, W. MS3 eliminates ratio distortion in isobaric
1217 multiplexed quantitative proteomics. *Nat. Methods* **8**, 937–940 (2011).
- 1218 72. McAlister, G. C. *et al.* MultiNotch MS3 enables accurate, sensitive, and multiplexed
1219 detection of differential expression across cancer cell line proteomes. *Anal. Chem.* **86**,
1220 7150–7158 (2014).
- 1221 73. Paulo, J. A., O’Connell, J. D. & Gygi, S. P. A Triple Knockout (TKO) Proteomics Standard
1222 for Diagnosing Ion Interference in Isobaric Labeling Experiments. *J. Am. Soc. Mass*
1223 *Spectrom.* **27**, 1620–5 (2016).
- 1224 74. Huttlin, E. L. *et al.* A tissue-specific atlas of mouse protein phosphorylation and
1225 expression. *Cell* **143**, 1174–1189 (2010).
- 1226 75. Elias, J. E. & Gygi, S. P. Target-decoy search strategy for mass spectrometry-based
1227 proteomics. *Methods Mol. Biol.* **604**, 55–71 (2010).
- 1228 76. Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-
1229 scale protein identifications by mass spectrometry. *Nat. Methods* **4**, 207–14 (2007).
- 1230 77. McAlister, G. C. *et al.* Increasing the multiplexing capacity of TMTs using reporter ion
1231 isotopologues with isobaric masses. *Anal. Chem.* **84**, 7469–7478 (2012).
- 1232 78. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing
1233 and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
- 1234 79. Fabregat, A. *et al.* The Reactome Pathway Knowledgebase. *Nucleic Acids Res.* **46**,
1235 D649–D655 (2018).
- 1236 80. Draizen, E. J. *et al.* HistoneDB 2.0: a histone database with variants—an integrated
1237 resource to explore histones and their variants. *Database* **2016**, baw014 (2016).
- 1238 81. The Uniprot Consortium. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids*

- 1239 *Res.* **47**, D506–D515 (2019).
- 1240 82. The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing
1241 strong. *Nucleic Acids Res.* **47**, D330–D338 (2019).
- 1242 83. Ghosh, P., Murugavel, P. & Sowdhamini, R. hRBPome : a central repository of all known
1243 human RNA-binding proteins Keywords. (2018). doi:<https://doi.org/10.1101/269043>
- 1244 84. Meers, M. P., Bryson, T. D., Henikoff, J. G. & Henikoff, S. Improved CUT&RUN chromatin
1245 profiling tools. *Elife* **8**, (2019).
- 1246 85. Corces, M. R. *et al.* The chromatin accessibility landscape of primary human cancers.
1247 *Science* **362**, (2018).
- 1248 86. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime
1249 cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–
1250 89 (2010).
- 1251 87. Fornes, O. *et al.* JASPAR 2020: update of the open-access database of transcription
1252 factor binding profiles. *Nucleic Acids Res.* (2019). doi:10.1093/nar/gkz1001
- 1253 88. R Core Team. R: A language environment for statistical computing. (2014).
- 1254